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1 
INTRODUCTION  
 
The term drug delivery covers a very broad range of techniques 
used to deliver therapeutic agents into the human body. The l imitations 
of the most obvious and trusted drug delivery techniques, those of the 
ingested tablet and of the intravenous (IV) / subcutaneous (SC) / 
intramuscular (IM) injections, have been recognized for some time 
now. The former delivers drug into the blood only through hepatic 
system, and hence the amount in blood stream may be much lower than 
the amount formulated into  tablet (i.e.,  it  has low bio -availability);  
furthermore, liver damage is an unfortunate side effect of many soluble 
tableted drugs. The injection mode of delivery can be used to deliver 
any size of drug molecule and is versati le in this regard, but suffer s 
from the obvious disadvantage of being invasive and painful, and the 
less obvious disadvantage of shortness of duration (for drugs with short  
half lives).  
 
To overcome some of these limitations, other modes of delivery 
of drugs into the body were investi gated, beginning in the early 1970s. 
Transdermal (through intact skin),  transmucosal,  transalveolar 
(inhalation, through lung tissue),  implantable (subcutaneous and deeper 
implants, delivery into surrounding t issue), and injectable (IM or SC) 
modes of delivery have all been explored extensively over the last  25 
years, with varying degrees of commercial and therapeutic success. 1 ,2  
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The delivery of drugs using skin as the port of entry is known as 
transdermal administration and the drug delivery systems are kn own as 
transdermal therapeutic systems or transdermal drug delivery systems 
or popularly known as transdermal patches. 1  
 
“Transdermal therapeutic systems are defined as self contained, 
discrete dosage forms which, when applied to the intact skin, deliver 
the drug(s), through the skin, at a controlled rate to the systemic 
circulation.”   
 
The success of this approach is evidenced by the fact  that there 
are currently more than 35 approved transdermal drug delivery 
products for the treatment of a wide variety o f conditions including: 
hypertension, angina, motion sicknesses, and recently contraception 
and urinary incontinence. There are also several products in late -stage 
development that will further expand transdermal drug delivery usage 
into new therapeutic areas,  including Parkinson ’s disease.1 ,2 ,3  
 
The polymers selected for the study are Ethyl cellulose and 
Hydroxypropylmethyl cellulose.  The drug taken up for the study is  
Repaglinide.  
 
Repaglinide, an antidiabetic chemically 2-ethoxy-4-[{[(15}-3-
methyl-1-[2-(piperdinyl) phenyl]  butylcarbamoyl} methyl]  benzolicacid  
(C2 7H3 6N2O4) It has half-life around 1 h and  bioavailable.  
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In the present study, transdermal patches of the Repaglinide were 
prepared using polymers like H ydroxypropylmethyl cellulose and Ethyl 
cellulose, both in different combination . These transdermal patches 
were characterized for their physicochemical properties including drug 
release.  
 
 In recent years considerable attention has been focused on the 
development of new drug delivery systems. The c onventional dosage 
forms such as tablets, capsules,  and parenterals  with the one exception 
of continuous intravenous infusion are inefficient because of several 
reasons. These dosage forms release the drug at faster rate initially 
leading to quick rise in  blood levels and thereafter there is an 
exponential fal l until  another dose is administered. This results in peak 
and valley pattern of drug levels in blood. Thus, for most of the time 
drug concentration is either above the therapeutic level leading to 
adverse reaction with potent drug or below it leading to 
ineffectiveness. The need to minimize blood level fluctuation of drug 
has led to the development of controlled drug delivery system.  
 
 Recently, it  is evident that the benefits of intravenous drug 
infusion can closely be duplicated, without its disadvantages,  by using 
the skin as a port  for drug administration, to provide continuous 
transdermal drug infusion in to systemic circulation.  
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 Transdermal drug delivery systems (TDDS) are designed to 
deliver the drug substances from the surface of the skin through i ts  
various layers into the systemic circulation. TDDS is the delivery of 
drugs through the skin to achieve systemic effects.  Transdermal 
patches control the delivery of drugs at controlled rates by employing 
an appropriate combination of hydrophilic and lipophillic polymers. 3 ,4  
 
Advantages 3 ,4  
 Prevents the variation in the absorption and metabolism 
associated with oral drug administration.  
 Prevents the risk and inconvenience of intravenous therapy.  
 Permits continuous zero-order drug administration and the use of 
drugs with short  biological  half -lives.  
 Increases the bioavailability and efficacy of drugs, since it 
bypasses hepatic first -pass elimination.  
 Provide a simple therapeutic regime, leading to good patient 
compliance that can be easily terminated by simple removal of 
the patch.  
 Transdermal medication delivers a steady infusion of a drug over 
an extended period of time. Adverse effects or therapeutic 
failures frequently associated with intermitte nt dosing can also 
be avoided.  
 Self-medication is possible.  
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Limitations 4 ,  5  
 The transdermal route of administration is unsuitable for drugs 
that  irritate or sensit ize the skin.  
 Only potent drugs are suitable candidates for transdermal 
delivery due to the natural limits of drug entry imposed by the 
skin permeability.  
 Technical  difficulties are associated with the adhesion of the 
systems to different skin types and under various environmental 
conditions,  and the development of rate controlling conditions.  
 Drugs requiring high blood levels to achieve an effect  are 
difficult to load into a transdermal system due to large physical 
amount of material required.  
 
Factors Affecting Transdermal Permeability  
The principal transport mechanism across mammalian skin i s  by 
passive diffusion, which is primarily the trans -epidermal route at 
steady state or through trans-appendageal route at initial non-steady 
state.  
 
The factors controll ing transdermal permeability are as follows :  
Partition Coefficient: Drugs possessing both lipid and water 
solubility are favourably absorbed through the skin.  Transdermal 
permeability coefficient shows a linear dependency on partition 
coefficient. A lipid/  water partition coefficient of one or greater is  
generally required for optimal trans dermal permeabili ty.  
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  The partition coefficient of a drug molecule may be altered by 
chemical modification of its  functional groups,  which can be done 
without affecting the pharmacological activity of the drug. It has been 
established that membrane partit ion coefficient increases exponentially 
as the length of the lipophilic alkyl chain increases. Varying the 
vehicle may also alter the parti tion coefficient of a drug molecule.  
 
pH condition: Solution whose pH values are very high or very 
low can be destructive to the skin. With moderate pH values, the flux 
of ionizable drugs can be affected by pH that alters the ratio of charged 
and uncharged species and their transdermal permeability.  
 
Penetrant concentration: Assuming membrane limited 
transport, increasing the concentration of dissolved drug causes a 
proportional increase in flux. At concentration higher than the 
solubility,  excess solid drug acts as a reservoir and helps to maintain a 
constant drug concentration for a prolonged period of time.  
 
Transdermal Drug Penetration through Skin 6 ,7 ,8  
Physiology of Skin  
Although the skin is  a large and logical target for drug delivery,  
its basic functions limit its utility for this purpose. The skin functions 
mainly to protect  the body from external insults (e.g. ,  h armful 
substances and microorganisms) and to contain all body fluids. It must 
be tough, yet flexible enough to allow for movement. The lipids in our 
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skin serve as poor conductors of electricity and can protect us from 
electrical current if  the need arises.  The skin also helps to regulate 
body temperature.  
 
There are two important layers to human skin:  the epidermis and 
the dermis. For transdermal delivery, drugs must pass through the two 
sub layers of the epidermis to reach the microcirculation of the dermi s.  
The stratum corneum (or the horny layer) is the top layer of the skin 
and varies in thickness from approximately 10 microns to several  
hundred microns,  depending on the region of the body. It is composed 
of layers of dead, flattened keratinocytes surrou nded by a lipid matrix,  
which together act as a brick -and-mortar system that is difficult to 
penetrate. The stratum corneum provides the most significant barrier to 
diffusion. In fact, the stratum corneum is the barrier to approximately 
90% of transdermal drug applications.  However, nearly all molecules 
penetrate it  to some minimal degree. Below the stratum corneum lies 
the viable epidermis. This layer is about ten times as thick as the 
stratum corneum; however, diffusion is much faster here due to the 
greater degree of hydration in the living cells of the viable epidermis.  
It  contains Langerhans' cells, which function as antigen presenting 
cells to the immune system. These cells are the targets for transdermal 
vaccine delivery.  Melanocytes in the viable ep idermis provide skin 
pigmentation. Below the epidermis lies the dermis, which is 
approximately one millimeter thick and 100 times the thickness of the 
stratum corneum. The dermis contains small vessels that  distribute 
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drugs into the systemic circulation an d to regulate temperature, a 
system known as the skin's microcirculation. The dermis also contains 
sensory neurons and a lymphatic network. The lymphatic removal of 
transdermally applied drugs has not been studied extensively.  
 
There are two main pathways by which the drugs cross the skin 
and reach the systemic circulation. The most direct  route is  known as 
the “ transcellular pathway” .  By this route, drugs cross the skin by 
directly passing through both the phospholipid membranes and the 
cytoplasm of the dead keratinocytes that constitute the stratum 
corneum. Although this is the path of shortest distance, the drugs 
encounter significant resistance to permeation. This is because the 
drugs must cross the lipophilic membrane  of each cell,  then the 
hydrophilic cellular contents containing keratin, and then the 
phospholipid bilayer  of the cell one more time. This series of steps is  
repeated number of times to traverse the full thickness of the stratum 
corneum. A few drugs have the properties to cross via this met hod. 
 
The more common pathway through the skin is via the 
intercellular route. Drugs cross the skin by this route and pass through 
the small spaces between the cells of the skin,  making the route more 
tortuous. Although the thickness of the stratum corneum  is only about 
20 µ m, the actual diffusion path of most molecules crossing the skin is  
on the order of 400 µ m. The 20 -fold increase in the actual path of 
permeating molecules greatly reduces the rate of drug penetration.  
9 
A less important pathway of drug p enetration is the foll icular 
route. Hair follicles penetrate through the stratum corneum, allowing 
more direct access to the dermal microcirculation. However, hair 
follicles occupy only 1/1000 of the entire skin surface area.  
Consequently,  very l ittle drug  crosses the skin via the follicular route.  
 
Figure 1: Diagram of skin along with transdermal patch  
 
Figure 2: Flow chart  of drug entry through skin into capillary vessels.  
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Basic Components of Transdermal Drug Delivery Systems 6 , 7 ,8  
 Transdermal drug delivery systems are designed to support  the 
passage of drug substance from the surface of skin, through its various 
layers, and into the systemic circulation. There are basic components 
of transdermal dosing system; which are those that cont rol the rate of 
drug delivery to the skin.  The components of devices include;  
 The drug substance  
 Polymer matrix  
 Permeation enhancer 
 Adhesives 
 Backing membrane 
 
1. The drug substance: Judicious choice of drug is critical  in 
the successful development of a transdermal product. The important 
drug properties that affect its diffusion from device as well as across 
the skin include molecular weight, solubility,  physical properties and 
melting point. The structure of the drug also affects the skin 
penetration. Diffusion of the drug in adequate amount to produce a 
satisfactory therapeutic effect is of prime importance. Other parameters 
such as skin irritation and clinical need should be considered before a 
drug is chosen.  
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 The following are some of the desirabl e properties of a drug for 
transdermal delivery.  
 The drug should have molecular weight less than 1000 Daltons.  
 The drug should have affinity for both lipophilic and hydrophilic 
phases.  
 The drug should have a low melting point.  
 The half-l ife of drug should be short .  
 The drug must not induce a cutaneous or allergic response.  
 The drugs, which degrade in gastrointestinal tract or inactivated 
by hepatic first pass effect are suitable candidates for 
transdermal drug delivery system.  
 
2. Polymer matrix: The polymers play a major role in transdermal 
drug delivery systems of drugs. The release of drug to the skin is 
controlled by drug free film known as rate controlling membrane. 
Polymers are also used in the matrix devices in which the drug is 
embedded in polymer matrix, which control the duration of release of 
drugs.  
 
The polymers should fulfil  the following requirements:  
 Molecular weight,  physical characteristics, and chemical 
functionality of the polymer must allow the diffusion of the drug 
substances at  desirable  rate.  
 The polymer should be chemically non-toxic, non reactive or it  
should be an inert drug carrier.  
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 The polymer must be easy to manufacture and fabricate into the 
desired product. It should allow incorporation of large amount of 
active agent.  
 The cost  of the polymer should not be expensive.  
 
The polymer controls the release of drug from the device. The 
polymer used should be stable, non -reactive with the drug, should 
allow the drug to diffuse properly and release through it.  Some of the 
useful polymers are as follows:  
 
Natural polymers      :  Cellulose derivatives, Zein, gelatin, gums and 
their derivatives etc.  
Synthetic elastomers : Polybutadiene, polysiloxane, acrylonitrile,  
butyl  rubber, neoprene etc.  
Synthetic polymers  :  Polyvinyl alcohol, polyvinyl chloride,   
polyethylene,  polyacrylate, polymethylmethacrylate etc.  
 
3. Penetration enhancers: Penetration enhancers are molecules,  which 
reversibly alter the barrier properties of the stratum corneum. They aid 
in the systemic delivery of drugs by allowin g the drug to penetrate 
more readily to viable tissues.  
 
They can be incorporated in transdermal formulation to obtain 
systemic delivery of the drug or for delivery of drugs to the deeper 
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layers of the skin or to achieve a given therapeutic effect with a 
reduced concentration of the active consti tuents.  
 
Penetration enhancer should have the following properties;  
 The material should be pharmacologically inert.  
 It  should be non-toxic, non-irritant , and have a low index of 
sensitization.  
 The penetration enhancing action should be immediate and 
should have suitable duration of effect.  
 The enhancer should be chemically and physically compatible 
with a wide range of drugs and pharmaceutical adjuncts.  
 The material should spread well on the skin.  
 It  should be odourless, tasteless, and colourless .  
 
They can be classified into three categories as shown in the Table 1.  
Table 1: Classification of penetration enhancers  
Lipophilic 
solvents 
Surface active 
agents 
Two component system 
Dimethyl 
sulfoxide 
Dimethyl 
Sodium lauryl  
sulphate 
Dodecylmethyl 
Propylene glycol, oleic 
acid,  
1-4-Butanediol 
 
 
 
 
 
14 
4. Adhesives  
The fastening of all transdermal devices to the skin using a 
pressure sensitive adhesive is  necessary.  
 
An adhesive system should fulfil  the following requirements .  
 It  should not cause irritat ion, sensitization or imbalance in the 
normal skin flora during its contact with skin.  
 It  should adhere to the skin aggressively.  
 It should be easily removable without leaving an unw ashable 
residue.  
 It  should be physically and chemically compatible with the drug, 
the excipients and enhancers.  
 It  should not affect the permeation of the drug.  
 The adhesive property should not deteriorate as the drug, 
enhancers and excipients permeate into the adhesive.  
 
 The types of adhesives commonly used in transdermal drug 
delivery system are:  
Rubber based adhesives: Natural gum (Karaya gum), olylisoprene, 
polybutene, and polyisobutelene.  
Polyacrylic based   : Ethyl acrylate,  2-ethylhexylacrylate,  iso -octyl  
acrylate.  
Polysiloxane based: Polydimethyl siloxane, polysilicate resins, 
sufloxane blends.  
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5. Backing membrane: It provides protection from external factors 
during application period. The backing layer must be impermeable to 
the drugs and enhancers , and as a result , it  is usually impermeable to 
water vapour. The most commonly used backing materials are 
metalized polyester laminated with polyethylene, Alupoly, polyester.  
 
Approaches Used in the Development of  Transdermal Drug Delivery 
Systems 1 ,  3 ,5 , 6 ,8  
 Four different approaches have been uti lized to obtain 
transdermal drug delivery systems:  
 
Membrane Permeation –  Controlled Systems  
In this type of system, the drug reservoir is totally encapsulated 
in a shallow compartment moulded from a drug -impermeable metallic 
plastic laminate and a rate controlling membrane, which may be micro 
porous or non-porous. The drug molecules are permitted to release only 
through the rate-controlling membrane. In the drug reservoir 
compartment, the drug solids are either d ispersed in a solid polymer 
matrix or suspended in an unleachable, viscous liquid medium such as 
silicone fluid to form a paste like suspension.  
 
A thin layer of drug compatible, adhesive polymer like silicone 
or polyacrylate adhesive may be applied to the  external surface of the 
rate controlling membrane to achieve an intimate contact of the 
transdermal system and skin surface. The rate of drug release from this 
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type of system can be tailored by varying the polymer composition, 
permeability coefficient and  thickness of the rate limiting membrane, 
and adhesive.  
 
The major advantage of membrane permeation controlled 
transdermal system is the constant release of drug. However, a rare risk 
also exists when an accidental breakage of the rate controlling 
membrane can result  in dose dumping or a rapid release of the entire 
drug content.  A few examples are as follows;  
 
1.  Nitroglycerin-releasing transdermal system (Transderm-
Nitro/Ciba, USA) for once a day medication in angina pectoris.  
2.  Scopolamine-releasing transdermal system (Transderm-
Scop/Ciba, USA) for 72 h. prophylaxis of motion sickness.  
 
 
Figure 3: Reservoir/membrane controlled transdermal patch system 8  
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Matrix Diffusion-Controlled Systems 
In this approach, the drug reservoir is prepared by ho mogenously 
dispersing drug particles in a hydrophilic or lipophilic polymer matrix.  
The resultant medicated polymer is then moulded into a medicated disc 
with a defined surface area and controlled thickness.  
 
The drug reservoir can be formed by dissolving  drug and 
polymer in a common solvent followed by solvent evaporation in a 
mould at an elevated temperature and/or vacuum. The drug reservoir 
containing polymer disc is then pasted on to an occlusive base plate in 
a compartment fabricated from a drug impermeable plastic backing. 
The adhesive polymer is then spread along the circumference to form a 
strip of adhesive rim around the medicated disc.   
 
The advantage of this system is the absence of dose dumping 
since polymer cannot rupture. One example of this t ype is 
Nitroglycerin-releasing transdermal therapeutic systems (Nitro -Dur and 
Nitro-Dur II /  Key Pharmaceuticals, USA).  
 
18 
 
Figure 4: Matrix controlled transdermal patch system 8  
 
 Adhesive Dispersion-Type Systems 
This system is a simplified  form of the membrane permeation -
controlled system. Here the drug reservoir is formulated by directly 
dispersing the drug in an adhesive polymer e.g. , poly (isobutylene) or 
poly (acrylate) adhesive and then spreading the medicated adhesive, by 
solvent cast ing or hot melt , on to a flat sheet of drug impermeable 
metallic plastic backing to form a thin drug reservoir layer. On the top 
of the drug reservoir layer, thin layers of non -medicated, rate 
controlling adhesive polymer of a specific permeability and con stant 
thickness are applied to produce an adhesive diffusion -controlled 
delivery system.  
 
For example, Isosorbide dinitrate releasing transdermal 
therapeutic system (Frandol tape/Yamanouchi, Japan) once -a-day 
medication of angina pectoris.  
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Micro reservoir Type or Micro sealed Dissolution Controlled 
Systems 
This system is a combination of the reservoir and matrix 
diffusion type drug delivery systems. The drug reservoir is formed by 
first suspending the drug solids in an aqueous solution of a water -
soluble l iquid polymer and then dispersing the drug suspension 
homogenously in a lipophilic polymer viz. silicone elastomers by high -
energy dispersion technique to form several discrete, unleachable 
microscopic spheres of drug reservoirs.  
 
The quick stabilization o f this thermodynamically unstable 
dispersion is accomplished by immediately cross -linking the polymer 
chains in-situ, which produces a medicated polymer disc with a 
constant surface area and fixed thickness. Positioning the medicated 
disc at the center and surrounding it with an adhesive produce a 
transdermal therapeutic system.  
 
 Nitroglycerin releasing transdermal therapeutic system (Nitro 
disc, Searle, USA) for once a day therapy of angina pectoris is a good 
example of this class.  
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REVIEW OF LITERATURE 
 
 Dandagi PM et al .1 8  prepared transdermal films of ketotifen 
fumarate using Eudragit  L 100, Hydroxypropyl  methyl cellulose and 
ethyl cellulose in combinations. Polyethylene glycol 400 was used as 
plasticizer. Permeation enhancers like dimethyl sulfoxid e and 
propylene glycol were used at different concentrations and in vitro 
drug release studies were carried out. They concluded that as the 
concentration of permeation enhancers increased, the drug release 
increased.  
 
 Mirohal A et al .2 2  prepared transdermal formulations of 
testosterone designed for biphasic delivery, containing a blend of 
polymeric components polyvinyl alcohol and polyvinyl pyrrolidone in 
isopropyl alcohol.  They reported that  the film initially showed burst 
effect and then sustained release  of testosterone.  
 
  Kulkarni RV et al .2 3  prepared and evaluated Eudragit RS 100 
films as rate controlling membrane for transdermal use and studied the 
effect of various plasticizers on the permeability and mechanical  
properties using verapamil hydrochloride as a model drug. They 
reported that films plasticized with polyethylene glycol showed higher 
permeability of verapamil hydrochloride as compared to Dibutyl  
phthalate. They also reported that permeability of drug decreased as 
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the concentration of dibutyl  phthalate and polyethylene glycol 
increased.  
 
  Panigrahi L et al .2 4  prepared pseudo-latex transdermal drug 
delivery system of terbutaline sulphate using combination of Eudragit  
RS 100 and eudraflex. They reported that  the drug release profiles from 
the patches followed apparent zero order patterns for a period of 12 h 
and skin permeation took place at a steady rate over a period of 12 h 
after which the rate was reduced.  
 
  Nagarajan M et al .2 5  prepared gelatin films of salbutamol 
sulphate transdermal drug delivery system using ethyl cellulose film 
as rate controlling membrane. They reported that controlled release of 
salbutamol sulphate was observed for a period of 12 -24 h and the drug 
release was found to depend on the proportion of gelatin used in drug 
reservoir layer. They showed that drug release from gelatin films can 
be controlled using ethyl cellulose film as rate controlling membrane.  
 
  Sankar V et al .2 6  prepared drug free polymeric films of ethyl 
cellulose to explore their suitability for transdermal application as rate 
controlling membrane using castor oil and glycerol as plasticizers. The 
permeability of free films were studied using nifedipine as model drug 
and reported that faster release was observed from ethyl  cellulose 
patches containing glycerol as plasticizer.    
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  Narasimha MS et al .2 7  carried out drug release studies from 
transdermal films of terbutaline sulphate using polymers such as 
hydroxypropylmethylcellulose and sodium carboxy methyl cellulose 
and reported that the hydroxypropylmethylcel lulose films showed a 
greater rate of release compared to that of sodium carboxy methyl 
cellulose across all the barriers used.  
 
  Mishra A et al .2 8  prepared transdermal formulations of 
testosterone designed for biphasic delivery, containing a blend of 
polymeric components polyvinyl alcohol and polyvinyl pyrrolidone in 
isopropyl alcohol.  They reported that  the film initially showed burst 
effect and then sustained release of testosterone.  
 
  Aqil  M et al .2 9  prepared and evaluated of monolithic matrix type 
transdermal drug delivery system of metoprolol tartarate using 
different concentration ratios of eudragit RL100 and polyvinyl 
pyrrolidone K-30. They reported that, the release of drug from the 
matrix was controlled and the skin permeation rate followed zero or der 
kinetics.  
 
  Gupta SP et al .3 0  prepared metoprolol tartarate transdermal drug 
delivery system for controlled release of drug for extended period of 
time using Eudragit  RL and Hydroxypropyl  methyl cellulose. They 
reported that, the transdermal drug delivery system exhibited better and 
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constant drug plasma profile for 24 h as compared to oral 
administration.  
 
  Jain GK et al .3 1  studied the effect of penetration enhancer (- 
limonene) on poly vinyl alcohol and polyvinyl pyrrolidone films 
containing verapamil  hydrochloride as drug. They reported that the 
drug permeation was enhanced by using - limonene as permeation 
enhancer.  
 
  Narasimha MS et al .3 2  prepared terbutaline sulphate transdermal 
films using various cellulose like sodium carboxy methyl cellulose,  
cellulose acetate, and ethyl cellulose. They studied the drug release 
from human cadaver skin and reported that, the films made from 
hydrophilic polymers showed a greater rate of release than that of 
hydrophobic polymers.  
 
  Das MK et al .3 3  studied the effect  of polymeric composition, 
drug content and plasticizer on the permeation of trazodone 
hydrochloride across the mouse epidermis for the development of 
transdermal therapeutic system and carried out in vitro  drug release 
studies.  They observed that, drug release increased with increase in 
amount of Eudragit  RL100 in the film. They demonstrated the potential  
use of fabricated pseudolatex transdermal films for sustained release of 
trazodone hydrochloride.  
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  J in K et al .3 4  carried out the feasibility studies of  using EVA for 
developing transdermal delivery of atenolol. They studied the effect  of 
drug concentration, temperature, and plasticizers on drug release from 
the atenolol-EVA matrix. They reported that  the drug release from the 
matrix increased with increase in temperature and drug loading.  
 
  Xiaoping Z et al .3 5  studied new type of copolymer membranes 
through photosynthesis of mixtures of three different monomers 2 -
hydroxy-3-phenoxy Propyl  acrylate, 4-hydroxy butyl acrylate and sec-
butyl t iglate by using clonidine as model drug. They reported that the 
prepared membranes showed near zero order permeation rates.  
 
  Michael HQ et al .3 6  studied the release of permeation enhancers 
from transdermal drug delivery system of drug -in-adhesive type using 
known enhancers from eight types of adhesive polymers. They showed 
that , enhancers released completely from the adhesive and the release 
rate depended on the types of adhesives used especially among the 
acrylic polymers. They also showed that acrylic adhesive and 
polyisobutylene adhesive showed slower drug release rate than sil icon 
adhesive.  
 
  Kulkarni RV et al .3 7  prepared drug free polymeric films of 
polyvinylpyrolidone (PVP), ethyl cellulose (EC), Eudragit  RS 100 
(Ed), and ethylene vinyl acetate (EVA) using verapamil HC l as model 
drug. The prepared films were evaluated for drug release study and 
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they showed that, drug diffusion followed nearly zero order kinetics 
and it is in the order of PVP > EC > Ed > EVA.  
 
  Arora P et al .3 8  prepared matrix type transdermal patches 
containing diclofenac diethylamine using different ratios of PVP and 
ethyl cellulose by solvent evaporation technique. The drug matrix fi lms 
were casted on a polyvinyl alcohol backing membrane and physical  
studies (moisture content, moisture uptake, and fla tness),  in vitro  
release studies were studied. They concluded that diclofenac 
diethylamine can be formulated into the transdermal matrix type 
patches for sustaining its release characterist ics and the polymeric 
composition (PVP/EC, 1:2) was found to be the  best among the 
formulations studied.  
 
  Kusum D et al .3 9  developed and evaluated free films and 
transdermal patches of ketorolac tromethamine using polymers and 
pressure sensitive adhesives. PVP and PVA were used as polymer 
matrix materials and acrylic and  silicone based pressure sensitive 
adhesives were used as adhesive matrix materials. They observed that  
the permeation of drug with Span 80 was more when compared to 
Tween 80, oleic acid, propylene glycol as enhancers.  
 
  Ramesh et al .4 0  developed transdermal reservoir patch of 
naloxone and evaluated for in vivo  s tudies, stability studies, and 
irritancy potential.  Propylene glycol and oleic acid have been used as 
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penetration enhancers and showed developed transdermal system of 
naloxone is efficacious, stable  and safe upon single and multiple dose 
application.  
 
Table 02: Commercially available TDDS 4 1 ,4 2  
Therapeutic 
agent 
Trade name          Manufacturer  Strengths 
available 
Clonidine Catapress-TTS Boeh-ringer 
Inyelheim 
2.5 mg, 5.0 mg,  
7.5 mg 
    
Estradiol  Estraderm Ciba 
 
25 µ g, 50 µ g, 100 
µ g 
Fentanyl  Duragesic Janssen 25 µ g, 50 µ g, 75 
µ g,  
100 µ g 
    
Nicotine Habitrol  
Nicoderm 
Nicotrol  
Prostep 
Basel  
Marion merrell  
Parke-davis  
Lederle 
21 µ g 
21 µ g 
15 µ g 
22 µ g 
    
Nitroglycerin  Deponit  
Nitrodisc 
Nitro-dur II 
Transderm nitro  
Schwarz Pharm 
Searle 
Key 
Ciba 
0.4 mg, 0.2 mg 
0.3 mg, 0.2 mg 
0.1 mg, 0.2 mg,  
0.6 mg 
0.1 mg, 0.2 mg,  
0.3 mg, 0.4 mg,  
0.6 mg 
    Scopolamine Transderm Scop Ciba 1.5 mg 
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Backing               Drug           Membrane          Adhesive       Liner/Skin 
Matrix 
 
Reservoir 
Drug-in-Adhesive 
Multi-Layer Drug-in-Adhesive 
Single-Layer 
 
Figure 5: Different transdermal drug delivery systems  
 
Keeping in view of the scientific reports enumerated in this 
chapter, suitable experimental methodology was adopted to obtain the 
answers for the questions given in the chapter “objectives” .  
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OBJECTIVES  
 The absorption of drugs through the transdermal route improves 
bioavailability of drugs that might otherwise be metabolized by first -
pass effect (pre-systemic drug elimination) during their passage 
through the gastrointestinal tract.  Drug absorption from the 
transdermal route is  mainly via passive diffusion through the lipoidal 
membrane. Thus, transdermal route of drug delivery has attracted the 
attention worldwide for optimizing the drug delivery. 3  
The objectives of the present investigation are : 
1.  To design suitable transdermal films of Repaglinide using 
bioadhesive polymers.  
2.  To characterize developed fi lms for their in vitro  drug release /  
permeation studies.  
3.  To formulate and evaluate the transdermal patches / films  for the 
following parameters;  
 Thickness uniformity.   
 Weight uniformity.  
 Swelling index.  
 Tensile strength.  
 Folding endurance.  
 Water vapour transmission rate.  
 Drug content uniformity.  
 In vitro  drug release studies.  
4.  To carry out short term stabil ity studies on the most satisfactory 
formulation as per ICH guidelines.    
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DRUG PROFILE 
REPAGLINIDE 9 ,1 0 ,1 1 ,1 2  
Structure:  It  is a racemic mixture with the following structure:   
 
            
      
                                                                                   OH 
           
  NH   
 
  N   
 
   
Molecular Formula     : C2 7H3 6N2O4 .  
Molecular Weight       :  452.5857 
IUPACName:2-ethoxy-4-[{[(15}-3-methyl-1-[2-
(piperdinyl)phenyl]butylcarbamoyl}methyl]benzoli
cacid 
Description: White to off-white crystalline powder;  hygroscopic.  
Solubility   : It is freely soluble in methanol and acetone; sparingly 
soluble in 95% ethanol and isopropanol; part ial ly soluble in water.  
Category : Repaglinide is a non sulphonyl urea oral hypoglycaemic 
agent  
Use    : Oral hypoglycaemic agent  
Melting Point  : Melting point is  in between 129 to 130  oC. 
O  
O  
O  
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Mechanism of action: Repaglinide is  a new class of non 
sulphonyl urea oral hypoglycaemic agent. It reduces the blood glucose 
by stimulating the release of insulin from the pancreas, dist inct from 
all other antidiabetic agent in their chemical structure, mechanism of 
binding to target channels in beta -cells, and mode of elimination. 
These agents have several desirable properties including a rapid onset  
and short duration of action and metabolism, and excretion by non-
renal routes. The bioavailability is approximately 45% and half life is  
1 -  3 hours.  
 
Pharmacokinetics: Repaglinide is  well absorbed from 
gastrointestinal  tract  but i t  subjected to high first pass metabolism in 
liver; the absolute bioavailabil ity is  about 56% Peak plasma 
concentration occurs in 1-3 hours after drug administration. It has high 
lipid solubility. Repaglinide is effective in lowering fasting blood 
glucose concentrations ( -13%), glycosolated haemoglobin(0.6-1.0%), 2 
hour postprandial  plasma glucose concentration -time profile.  
 
Therapeutic Uses: It  has antidiabetic  activity on type two 
diabetes mainly which occurs in youths and in old aged people and 
with combination with drugs of antidiabetic class of type one is fo und 
to be more effective than the plain drugs used in treatment of type one 
diabetes. at higher doses calcium channel blocking activity may 
contribute.  
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Adverse Effects: Acute renal failure and renal abnormalit ies 
have been reported in patients with heart  failure who also suffered 
from diffuse vascular disease and/or renal impairment.  
 
Contraindications:  
Therapy with repaglinide is  contraindicated in patients with  
1.  Congestive heart  failure requiring pharmacological treatment  
2.  Renal disease or renal dysfunction, which may also result 
from conditions such as cardiovascular collapse, acute 
myocardial  infarction and septicaemia.  
3.  Known hypersensitivity to repaglinide.  
4.  Acute or chronic metabolic acidosis,  including diabeti c 
ketoacidosis with or without coma. Diab etic ketoacidosis 
should be treated with insulin.  
Storage: Protect from moisture,  Stored in tight l ight -resistant 
container.  
Dose: 2, 4, 10, 20 and 25.0 mg.  
 
POLYMER REVIEW  
1)Hydroxy Propyl Methyl Cellulose: 1 3 ,1 4 ,1 5  
Non Proprietary Name :  
British pharmacopoeia: Hypromellose             
United State Pharmacopoeia:  Hydroxy Propyl Methyl cellulose  
Synonyms   :   Methocel,  HPMC 
Chemical Name  :   Cellulose, 2-Hydroxypropyl methyl ether  
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Empirical Formula       :   HPMC is a partially o -methylated and o- 
(2-Hydroxy propylated)  
Structural Formula  :  
 
O
OH
OH
CH
2
OCH
2
COONa
O
O
OH
CH
2
OCH
2
COONa
OH
O
n 
                      
Molecular Weight  : Approximate 10000 to 1500000.  
Functional Category :  Tablet binder, coating agent, and film former.  
Pharmacopoeia  :   BP and USP.  
Description   :   Odourless , tasteless, white or creamy white  
        fibrous or granular powder.  
pH    :    5.5 to 8.0.  
Aqueous Viscosity  :   (1% w/v) HPMC K4M = 3000 to 5600 cp.  
                                       HPMC K15M = 11250 to 21000 cp.  
 
Solubility   :   Soluble in cold water, insoluble in alcohol,   
        ether,  and chloroform, but soluble in a  
        mixture of methylene chloride and  
        methanol.  
Stability    :  Stable in dry condition from pH 3.0 to 11.0.  
Storage Condition   :   It  is hygroscopic in nature. Should be stored  
       in well-closed container, in a cool and dry  
       place.  
33 
Incompatibilities   : Incompatible with some oxidizing agents.  
      Since it’s non-ionic, hydroxypropylmehyl    
                                     cellulose will  not complex with metallic  
                                     effect.                     
Safety   : It’s generally regarded as a nontoxic and  
      non-irritant material although excessive oral  
      consumption may have a laxative effect .  
Application  : HPMC is widely used in oral and topical  
      pharmaceutical formulations. In oral   
      products, it  primarily used tablet binder and  
      extended release matrix.  
ETHYLCELLULOSE1 6  
Synonym : Ethylcellulosum 
Functional category :  Coating agent, tablet binder, viscosity-increasing 
agent. Description: Ethyl cellulose is a tasteless, free -flowing, white 
to light tan coloured powder.  
Solubility: Ethyl cellulose practically insoluble in glycerine,  
propylene glycol and water. Ethyl cellulose is soluble in  chloroform, 
methyl acetate, tetrahydrofuran, and in mixture of aromatic 
hydrocarbons with ethanol (95%).  
Stability and storage conditions: Ethyl cellulose is a stable,  slightly,  
hygroscopic materials. It is chemically stable to alkalis, both dilute 
and concentrated, and to salt solutions, although it  is  more sensitive to 
acidic materials than cellulose esters. The bulk materials should be 
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stored in a dry place, in a well closed container at a temperature 
between 7-32 ºC.  
Incompatibilities: Incompatible with paraffin wax and 
microcrystalline wax.  
Application: Ethyl cellulose is widely used in oral and topical  
pharmaceutical  formulations. The main use of ethyl cellulose in oral 
formulations is as a hydrophobic coating agent for tablets and granules.  
Ethyl cellulose coatings are used to modify the release of drug. Ethyl 
cellulose, dissolved in an organic solvent or solvent mixture, can be 
used on its  own to produce water -insoluble films. Higher viscosity 
ethyl cellulose grades are used to produce stronger and t ougher films. 
In topical formulations, ethyl cellulose is  used as a thickening agent in 
creams, lotions or gels, provided an appropriate solvent is used. Ethyl 
cellulose is additionally used in cosmetics and food products.  
 
PLASTICIZER REVIEW 
1) DIBUTYL PHTHALATE 1 7  
Synonym  : Butyl phthalate; DBP  
Chemical Name :   Dibutyl benzene,1,2-dicarboxylate  
Structural Formula:  
 
Molecular Formula  : C1 6H2 2O4  
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Molecular Weight  : 278.3  
Description   :  A clear, colourless  or faintly yellow,  
     somewhat viscous.  
Density   :  1.045 
Boiling Point   :  330 oC 
Refractive Index          :  1.492 to 1.495 
Solubility   :  Very soluble in ethanol, ether,  aceto ne,  
     benzene, 1 in 2500 parts of water,   
     miscible with ethanol, ether and most  
     other organic solvents.  
PERMEATION ENHENCHER REVIEW 
1) DIMETHYL FORMAMIDE :1 7  
Synonyms: DMF,Dimethylformamide, N,N-dimethylformamide, DMFA  
Description: Colourless l iquid,  miscible with water and the majority 
of organic liquids.  
Chemical Name:   N,N-dimethylmethanamide  
Structural Formula:  
 
Molecular Formula    : C3H7NO 
Molecular Weight      :  73.09 g/mol  
Density                         : 0.944 g/cm3  
Boiling Point             :  153 °C  
Refractive Index     : 1.4305 (20 °C)  
36 
Viscosity:  0.92 CP at 20 °C  
Solubility : Miscible with water, alcohol,  ether;  acetone, benzene.  
Storage Condition : Stored in air tight glass containers, protected 
from light.  
(2) DIMETHYL SULFOXIDE: 1 8  
Synonyms : Dimethyl sulfoxide, DMSO, Methyl sulfoxide 
Description : A colourless hygroscopic odourless  liquid or crystals.  
Structural Formula:  
Molecular Formula  : C2H6  OS 
Specific Gravity      : 1.100 to 1.104  
Molecular Weight    : 78.13 
Solubility    : Miscible with water, alcohol,  ether, acetone,  
      benzene. 
Storage condition  : Store in air tight glass containers,  protect  
      from light.  
Application : DMSO is highly polar substance which has exceptional 
solvent properties for both organic and inorganic chemicals and is 
widely used as an industrial solven t. The principal use of DMSO is as a 
vehicle for drug, it  aids penetration of drug into the skin, mucus layer 
and so may enhance the drug ’s bioavailability.  
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SURFACTANT REVIEW 
1)  TWEEN  801 9  
Synonyms   :  Polyoxyethylene 20 oleate, Tween 80,  
     Polysorbate 80.  
Chemical Name  :  Polyoxyethylene 20 sorbitan mono  oleate.  
Empirical Formula  :  C6 4  H1 2 4  O2 6  
Molecular Weight   :  1310 .  
Functional Category  :  Emulsifying agent; non-ionic  
     surfactant; solubilizing agent,  wetting  
     agent.  
Description   :  Polysorbates have a characteristic  
     odour and somewhat bitter in taste.    
     Their colour and physical form at 25 oC  
     is yellow oily liquid.  
2) POLYETHYLENE GLYCOL-4002 1  
Synonyms:  poly (ethylene oxide) (PEO) or polyoxyethylene (POE), 
polyether’s 
Structural Formula:  
Description   :  A clear, colourless , viscous and  
     practically odourless  liquid having a  
     sweet, sl ightly acrid taste resembling  
     glycerol.                  
Molecular Formula  :   C2 nH4 n +2On +1 
Molecular Weight  : 380-420 g / mol  
Density    : 1.128 g / cm³  
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Boiling Point   : 182 - 287 °C 
Viscosity    : 90.0 cSt at 25 °C, 7.3 cSt at 99 °C  
Solubility   :  PEG is soluble in water, methanol,   
     benzene, dichloromethane and insoluble  
     in diethyl ether and hexane.                                          
Storage Condition  : Store in air tight glass containers,   
     protect from light.  
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MATERIALS AND METHODS 
 Distilled water was prepared in the laboratory using all glass 
distillation apparatus.  
Experimental Methods  
Analytical methods of Repaglinide 
 Determination of λ ma x  of repaglinide in 0.1 N HCl solution  
 Determination of λm ax  of repaglinide in pH 7.4 phosphate buffer 
solution 
 Calibration curve of  repaglinide 0.1N HCl solution  
 Calibration curve of repaglinide in pH 7.4 phosphate buffer 
solution 
Preformulation Studies  
 Determination of melting point  
 Determination of partition coefficient  
 Determination of drug-excipients compatibility studies  
Evaluation of film /  patch formulation  
 Thickness uniformity  
 Weight uniformity 
 Tensile strength  
 Swelling index 
 Folding endurance 
 Water vapour transmission rate  
 Drug content uniformity of films  
 In vitro  drug release studies  
 Stabili ty studies  
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Preparation of Solutions 4 2  
 Phosphate buffer (pH 7.4) solution: Fifty ml of 0.2M potassium 
dihydrogen phosphate was taken in 200 ml volumetric flask, to which 
39.1 ml of 0.2 M sodium hydroxide solution was added and the volume 
was made up to the mark with dist illed water.  
Potassium dihydrogen phosphate (0.2 M) solution: Potassium 
dihydrogen phosphate (27.218) g was added to 1000 ml volumetric 
flask containing distilled water and the volume was made up to the 
mark with dist illed water.  
Sodium hydroxide (0.2 M) solution: Eight gram of sodium 
hydroxide was taken in 1000 ml volumetric flask containing distilled 
water and volume was made up to the mark with distilled water.  
Analytical Methods  
Determination of λma x  of repaglinide in Phosphate Buffer (pH 7.4) 
Solution : 
Preparation of Repaglinide standard stock solution (200 µg/ml) in 
methanol: Standard stock solution of repaglinide was prepared by 
dissolving accurately weighed 10 mg of repaglinide in the little 
quantity of methanol in 50 ml volumetric flask. The volume was then 
made up to 50 ml by using methanol to obtain the solution of 200 
g/ml.  
Scanning of repaglinide by UV-spectrophotometer in 0.1 N 
HCl solution: From the standard stock solution, 1 ml was pipetted into 
a volumetric flask. The volume was then made up to 20 ml with 0.1 N 
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HCl solutions. The resulting solution containing 10 g/ml was scanned 
between 200 - 400 nm.  The max  was found to be 237 nm.  
 
Figure 6:  UV spectrum of Repaglinide in 0.1 N HCl solutions  
(10 g/ml).  
Calibration curve of Repaglinide in 0.1 N HCl solution: From 
the repaglinide standard stock solution (200 g/ml), 1 ml was pipetted 
and diluted to 20 ml by using 0.1 N HCl solutions.  From this solution, 
appropriate aliquots were taken into different volumetric flasks and 
made up to 10 ml with 0.1 N HCl solutions, so as to get drug 
concentrations from 2.5g/ml to 20.0 g/ml.  The absorbencies of these 
drug solutions were estimated at max  237 nm.  This procedure was 
performed in triplicate to validate the calibration curve.  The data are 
given in Table 03.  A calibration curve was constructed as shown in 
Figure 07.  Calibration equation and regression value a re shown in 
Figure 07.  
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Table 3: Data for calibration curve of repaglinide 0.1 N HCl 
solution at 237 nm 
Sl. 
No.  
Concentration,  
g/ ml  
* Absorbance at 237 nm 
AM +  SD  
1 0 0.000   0.000 
2 2.5 0.115   0.002 
3 5.0 0.216   0.005 
4 7.5 0.345   0.007 
5 10.0 0.483   0.006 
6 12.5 0.552   0.007 
7 15.0 0.675   0.007 
8 17.5 0.798   0.002 
9 20.0 0.903   0.004 
   
 
           * Each value was an average of three determinations  
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Figure 7:Standard plot of repaglinide in 0.1 N hydrochloric  
acid solutions.  
Scanning of Repaglinide by UV-spectrophotometer in 
phosphate buffer (pH 7.4) solution: From the standard stock solution, 
1 ml was diluted to 20 ml with phosphate buffer solution (pH 7.4). The 
resulting solution containing 10 g/ml was scanned between 200 and 
400 nm.  The max  was found to be 237 nm.  
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Figure 8:  UV spectrum of Repaglinide in 7.4 pH phosphate buffer 
solution (10 g/ml) 
Calibration curve of Repaglinide in phosphate buffer solution 
(pH 7.4): From the repaglinide standard stock solution (200 g/ml), 1 
ml solution was diluted to 19 ml using 7.4 pH phosphate buffer 
solutions. Appropriate aliquots were taken into different volumetric 
flasks and made up to 10 ml with phosphate buffer solution (pH 7.4), 
so as to get drug concentrations of 2.5 g/ml to 22.5 g/ml.  The 
absorbencies of these drug solutions were estimated at max  237 nm.  
This procedure was performed in triplicate to validate the calibration 
curve. The data are given in Table 04.  A calibration curve was 
constructed as shown in Figure 09. Calibration equation and regression 
value are shown in Figure 09.  
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Table 4: Data for calibration curve of repaglinide phosphate buffer 
solution (pH 7.4)  at  237nm 
Sl. 
No.  
Concentration,  
g/ ml  
* Absorbance at 237 
nm 
1 0 0.000   0.000 
2 2.5 0.117   0.002 
3 5.0 0.218   0.004 
4 7.5 0.347   0.008 
5 10.0 0.487   0.007 
6 12.5 0.557   0.004 
7 15.0 0.675   0.003 
8 17.5 0.798   0.004 
9 20.0 0.907   0.005 
10 22.5 1.105   0.006 
   
          * Each value was an average of three determinations  
 
Figure 9:Standard plot of repaglinide in phosphate buffer solution  
(pH 7.4)  
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Interference of Polymers in the Estimations  
Scanning of HPMC solutions (0.2%) in phosphate buffer 
solution (7.4 pH):  It  was necessary to identify the incompatibility of 
polymer and drug for the analysis.   Keeping in view of the 
concentration of polymer, an empirical concentration was fixed for the 
study of analysis.  Solutions of polymers were prepared as per the 
concentrations given in the Table 05. The solutions were scanned in 
UV- region, 200-400 nm, using corresponding blank solutions.   Figures 
10- 12 represent the UV scans of polymeric solutions.  
 
 
Figure 10:UV- spectrum of HPMC in 7.4 pH phosphate buffer solution  
(0.2 % w/v)  
 
237nm 
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Figure 11:  UV- spectrum of Ethyl cellulose (0.1% w/v) in ethanol.  
 
 Table 5: Data for estimation of interference of polymers   
Polymer Concentration % 
w/v 
Solvent Absorbance at 241 
nm 
HPMC K 100 
Ethyle 
cellulose 
0.2 
0.2 
 
Buffer 
Methanol  
 
0.1043 
0.1063 
 
At the wavelength of 237 nm, the polymer solutions  had not  
shown appreciable absorbance. In other words; polymer does not 
interfere with the absorption of drug .   
Fourier Transform Infrared Spectroscopy  
 The pure drug (Repaglinide) and polymers were subjected to IR 
studies alone and in combination.  Pure d rug/pure polymer/combination 
of drug-polymer were mixed with 100 mg of potassium bromide. 
Thorough grinding in smooth mortar can effect  mixing. The mixtures 
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were then placed in the sample holder  of the instrument. These were 
analyzed by FTIR to study the interference of polymer for drug 
analysis.  
Preparation of Transdermal Films / Patches of R epaglinide 
Transdermal films containing repaglinide were prepared by the 
solvent evaporation technique for the formulations shown in Table 06. 
Solution of HPMC K-100 and Ethyl  cellulose were prepared separately 
in ethanol. The two polymeric solutions were mixed to which weighed 
amount of repaglinide was added slowly.  To the mixture, 4 drop 
dibutyl phthalate (0.15 mg) .  The drug-polymer solution was casted in a 
glass mould of 15 cm2  (3 × 5 cm2).  The mould was kept aside for 
drying at room temperature for 24 h. Inverted plastic funnel was placed 
over the mould to prevent the current of air. After drying the fi lms 
were peeled from glass mould, wrapped in aluminium foil , and  
preserved in desiccator for further studies.  In the literature, the terms 
“patches”  and “films”  were used synonymously.   In this thesis, the two 
terms are carefully used to avoid confusion.  The term “patch”  refers to 
1 x 1 cm2  size formulations and the term “film”  refers to the 
formulation of bigger size than patch.   
 
 
 
 
 
 
49 
Table 6:  Composit ion of different formulations containing Repaglinide 
INGEDIENTS F1 F2 F3 F4 F5 
Repaglinide 10mg 10mg 10mg 10mg 10mg 
Ethyl 
cellulose 
400mg 300mg 200mg 100mg 0mg 
HPMC K-100 0mg 100mg 200mg 300mg 400mg 
DBP 0.015mg 0.015mg 0.015mg 0.015mg 0.015mg 
 
Preformulation Studies  
 The following Preformulation studies were performed for 
Repaglinide and polymers;  
1.  Determination of melting point.  
2.  Determination of partition coeffici ent.  
3.  Determination of drug-excipients compatibility studies.  
1. Determination of melting point  
Melting point of the drug was determined by taking small amount 
of drug in a capillary tube closed at one end.  The capillary tube was 
placed in a melting point  apparatus and the temperature at which drug 
melts was recorded. This was performed thrice and average value was 
noted.  
2. Determination of partition coefficient 4 3 ,  4 4  
The oil-water parti tion coefficient is  a measure of lipophilicity 
of a molecule, which can be used to predict its capabili ty to cross 
biological membrane. One of the most common ways of measuring 
partition coefficient is shake flask method.  
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Procedure:  The Repaglinide was added li ttle at once into 5 ml of 
n-octanol until saturated solution was  obtained. This solution was 
filtered to get a clear solution.  Three ml of the saturated solution was 
mixed with 2 ml of fresh n-octanol.  In total 5 ml of      n-octanol 
containing repaglinide was mixed with 15 ml of water. Then two 
phases were allowed to equilibrate at 37 oC for 24 h, on cryostatic 
constant temperature shaker bath (Research and Test Equipments, 
Bangalore, India).  The concentration of the drug in the    aqueous 
phase and organic phase was determined by UV  spectroscopic method 
after necessary dilution. The apparent partition coefficient (Kp)  was 
calculated as the ratio of drug concentration in each phase by the 
following equation.  
 
where,  Co rg  is   concentration of drug in organic phase and Ca q  is the 
concentration of drug in aqueous phase .  
3. Drug–  excipients compatibility studies 3 3  
In the preparation of film formulation, drug and polymer may 
interact  as they are in close contact  with each other, which could lead 
to the instability of drug. preformulation studies regarding the drug -
polymer interaction are therefore very critical in selecting appropriate 
polymers. FT-IR spectroscopy was employed to ascertain the 
compatibility between repaglinide and the selected polymers.  The pure 
drug and drug with excipients were scanned separately.  
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Procedure:  Potassium bromide was mixed with drug and/or 
polymer and the spectra were taken. FT-IR spectrum of repaglinide  was 
compared with FT-IR spectra of repaglinide with polymer. 
Disappearance of repaglinide  peaks or shifting of peak in any of the 
spectra was studied.  
Thickness Uniformity of Films 2 2 ,2 3 ,2 4 ,2 6  
The thickness of each film was measured by using screw gauze. 
The thickness was measured at six different places on each film and the 
average thickness of the film was taken as the thickness of the film .  
Weight Uniformity of Patches 2 2 ,2 3 ,2 4 ,2 6  
The patch of size 1x1 cm 2  was cut and weight of each patch was 
taken individually,  the average weight of the patch was calculated.  
Swelling Index2 7  
 Weight increase due to swelling and area increase due to 
swelling were studied.  
a) Weight increase due to swelling: The drug-loaded patch of 
size 1 x 1 cm2  was weighed on a pre-weighed cover slip.  It  was kept in  
a petridish and 50 ml of phosphate buffer (pH 7.4) solution was added. 
After every five min, the cover slip was removed, wiped with tissue 
paper, and weighed up to 30 min. The difference in the weights gives 
the weight increase due to absorption of water and swelling of patch.  
b) Area increase due to swelling : The drug loaded patch of size 
1 x 1 cm2  was cut and placed in a petridish containing 50 ml of 
phosphate buffer (pH 7.4) solution.  A graph paper was placed beneath 
the petridish and was clearly visible, which facilitated the measurement 
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of increase in the area. An increase in the length and breadth of the  
patch was noted at five min intervals for 60 min and the area was 
calculated. The percent swelling, % S  was calculated using the 
following equation:  
X t  -  Xo  
%S  =                   x 100  
Xo  
 
where X t  is the weight or area of the swollen patch after time t  and Xo  
is the original patch weight or area at zero time.  
Tensile Strength of Films 2 8 ,  2 9  
Tensile strength of the film was determined with Universal  
Strength Testing Machine (Hounsfield,  Slinfold, Horsham, U.K.) as 
shown in Figure 13 .  The sensitivity of  the machine was 1 gram.  It 
consisted of two load cell  grips. The lower one was fixed  
 
Figure 12: Universal  Strength Testing Machine  
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and upper one was movable. The test film of size (4   1 cm2) was fixed 
between these cell  grips and force was gradually  applied ti l l  the film 
broke.  The tensile strength of the fi lm was taken directly from the dial 
reading in kg. Tensile strength is expressed as follows;  
                                                                 Tensile load at  break  
                              Tensile strength =   
                                                                 Cross sectional area  
Folding Endurance 3 0 ,  3 1  
The folding endurance was measured manually for the prepared 
films. A strip of film (4 x 3 cm) was cut and r epeatedly folded at  the 
same place till  it  broke. The number of times the film could be folded 
at the same place without breaking gave the value of folding 
endurance.  
Water Vapour Transmission (WVT) Rate 3 0 ,3 1   
For this study vials of equal diameter were u sed as transmission 
cells. These cells were washed thoroughly and dried in an oven, about  
1 g of fused calcium chloride was taken in cells and the polymeric 
patches measuring 1 cm 2  area were fixed over the brim with the help of 
an adhesive.  The cells were weighed accurately and initial weight was 
recorded, and then kept in a closed desiccator containing saturated 
solution of potassium chloride to maintain 63 % RH. The cells were 
taken out and weighed after 72 h.1 4  The amount and rate of water 
vapour transmitted was calculated by the difference in weight using the 
formula:  
WVT rate = WL/S 
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where,  W is the water vapour transmitted in grams, L  is the thickness 
of the patch in cm, and S is the exposed surface area in square cm.  
Drug Content Uniformity 3 0 ,3 1  
The films were tested for the content uniformity.   The film of 
size 2   2 cm2   was cut and placed in a volumetric flask. Ten ml of 
methanol was added and the contents were stirred in a shaker bath for 
24 h to dissolve the film.  Subsequent dilutions were made with 
phosphate buffer (pH 7.4).  The absorbance of the solution was 
measured against the corresponding blank solution at 241 nm using 
UV-VIS spectrophotometer. The experiment was repeated two more 
time to validate the result.  
In Vitro  Release Studies of Repaglinide from Transdermal Films  
In vitro  release studies by using dissolution apparatus (Paddle 
over disk method):3 2 ,3 3   The drug release was determined using U.S.P. 
dissolution test  apparatus (paddle over disk type method) thermo stated 
at 37±1 oC and stirred at a rate of 50 rpm. Sink condition was 
maintained throughout the study.  
Each film was fixed on glass slide with the help of cyanoacrylate 
adhesive, so that the drug could be released only from upper face. The 
slide was immersed in the vessel containing  900 ml of phosphate 
buffer, pH 7.4, solution. Aliquots of 5 ml of sample were withdrawn 
with graduated pipette at every one hour time intervals up to 24 h 
replacing with equal volume of phosphate buffer.  
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The sample was analyzed spectrophotometrically at  237 nm and 
the cumulative amount of drug released at  various time intervals was 
calculated. The test  was carried out in triplicates.  
Stability Studies3 4  
Stabili ty  is defined as the ability of particular drug or dosage 
form in a specific container to remai n within its physical , chemical, 
therapeutic,  and toxicological specification. Drug decomposition or 
degradation occurs during stability, because of chemical alteration of 
the active ingredients or due to product instability,  lowering the 
concentration of the drug in the dosage form. The stability of 
pharmaceutical  preparation should be evaluated by accelerated stability 
studies. The optimized formulation of repaglinide films was selected 
for the stability studies.  The accelerated stability studies were car ried 
out according to ICH guidelines by storing the samples at  40 + 2 oC 
and 75 + 5% RH for 1 month.  These samples were analyzed and 
checked for changes in physical appearance and drug content at an 
interval of 7 days.  
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RESULTS AND DISCUSSION  
 
Preformulation Studies  
 The following Preformulation studies were performed for 
repaglinide.  
Melting Point  
Melting point of repaglinide was determined by capillary tube 
method and it was found to be 130   ± 1  (n = 3). This value is same as 
that  of the literature citation.  
Partition Coefficient  
Partition coefficient determination study of repaglinide was done 
with n-octanol and water. The logarithmic value of partition coefficient 
(log pka) of repaglinide was found to be 3.497. This indicates that  
repaglinide is  lipophillic in nature.  
 
Table 7: Data of various preformulation studies  
Sl. no.      Drug   Melting 
point 
Partition 
coefficient 
    1.  Repaglinide 130  ± 1 
 
5.90 
     *Standard deviation, n = 3 
Drug –  Excipients  Compatibility Studies 
As described in the methodology section the Fourier Transform 
infrared spectroscopy studies were carried out for pure drug along and 
along with polymers.   The results are summarized as follows.  
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IR spectra of Repaglinide, HPMC K-100, Ethyl  cellulose, alone 
and their combinations are shown in Figures 15 to 19 .    An IR spectrum 
of pure repaglinide shows the following peaks.  
 
Table 8:FTIR spectrum of pure repaglinide  
Bond (stretching)  Wave number (cm -1) 
-NH 
-OH 
-CH 
3344.93 
2922.59 
2630.43 
 
The above peaks can be considered as characteristic peaks of 
repaglinide.  These peaks were not affected and prominently observed 
in IR spectra of repaglinide along with polymers as shown in Figures 
13 to 17.  This indicates there is  no interaction.  
 
Figure  13:  IR spectrum of repaglinide pure  
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Figure  14: IR spectrum of HPMC pure  
 
 
Figure15: IR spectrum of repaglinide-HPMC mixture  
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Figure 16: IR spectrum of ethyl cellulose pure  
 
Figure 17: IR spectrum of repaglinide –  ethyl cellulose mixture  
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EVALUATION OF FILMS 
Thickness  
With the help of screw gauze, the thickness of films was 
measured and the average thickness was noted. The thickness results 
are given in Table 9. The result indicates that there was no much 
difference in the thickness within the form ulations.   The order of the 
thickness of films is F3< F2< F1< F5< F4  
 
Table 9: Thickness uniformity of F 1  to F5  film formulations  
Sl. 
no.  
Formulation 
code 
                    Average Thickness (mm) 
Trial 1 Trial 2 Trial 3 Mean   S.D.* 
1 F1  0.222 0.227 0.224 0.224 ± 0.002 
2 F2  0.219 0.221 0.223 0.221 ± 0.002 
3 F3  0.218 0.215 0.217 0.217 ± 0.002 
4 F4  0.296 0.291 0.297 0.295 ±0.003 
5 F5  0.284 0.281 0.285         0.283 ± 0.002 
   *Standard deviation, n = 3  
Weight Uniformity  
Drug loaded patches (1 x 1 cm2) were tested for uniformity of 
weight and the results of weight uniformity are given in Table 11.  
Lesser S.D. values indicate that the patches were uniform.  The order 
of the weight of films is F 3< F2  < F1  < F5< F4 .  This is  in agreement with 
the uniformity of the thickness.  Perusal to Table 11 indicates that  
patch F4  exhibited highest weight.  It  could be because of the reason 
explained in the thickness uniformity.  
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Table 10: Weight uniformity data of F 1  to F5  patch formulations  
Sl.   
no.  
Formulation 
code 
Average weight (mg)  
Trial 1 Trial 2 Trial 3 Mean   S.D.* 
1 F1  20.73 20.26 19.48 20.15 ± 0.396 
2 F2  18.29 18.30 19.18 18.59  ± 0.243 
3 F3  17.32 17.89 18.12 17.77  ± 0.264 
4 F4  23.41 22.39 22.63 22.81 ± 0.160 
5 F5  21.78 22.56 21.42 21.92 ± 0.416 
   *Standard deviation, n = 3  
Swelling studies of  the patches:  The swelling of the drug loaded 
patches of size 1 x 1 cm 2  was studied up to 30 min in case of change in 
weight and 60 min in case of change in area. The swelling of the 
patches were observed in phosphate buffer solution (pH 7.4).  The data 
for increase in weight due to swelling are given in Tables 11 to 15 for 
patches F1  to F5 ,  respectively.  The entire data are shown in Figure 18. 
Swelling was more pronounced in patch F 4  and F5  which contain more 
of HPMC (hydrophilic polymer).  Patches F 1  and F2  showed lesser 
swelling (weight basis), may be due to the presence of higher 
concentrations of Ethyl cellulose hydrophobic polymer.  The order of 
patches for their increase in weight due to swelling is  F1< F2< F3< F4< 
F5 .   Further, it  should be verified with increase in area due to swelling.  
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Table11: Swelling studies Repaglinide of patch F1  -Change in weight  
Sl. 
no.  
Time 
(min) 
Weight of  
patch (mg) 
AM ± S.D.  
Increase in  
weight (mg) 
AM ± S.D.  
Percent 
increase 
in weight* 1 
2 
3 
4 
5 
6 
7 
0 
5 
10 
15 
20 
25 
30 
20.151 ± 0.394 
27.856 ± 1.512 
38.728 ± 2.168 
43.748 ± 2.378 
50.174 ± 2.219 
59.262 ± 4.705 
64.393 ± 2.252 
0 
7.707 ± 1.889 
18.577 ± 2.663 
23.597 ± 1.927 
30.023 ± 1.786 
39.111 ± 4.257 
44.242 ± 1.821 
0 
38.231  ± 3.325 
92.178 ± 2.040 
117.108 ± 3.0650
148.990 ± 3.0430
194.089 ± 13.059
219.552 ± 2.4780
* Each reading was an average of three determinations  
 
Table12: Swelling studies of repaglinide patch F 2  -Change in weight  
Sl. 
no.  
Time 
(min) 
Weight of  
patch (mg) 
AM ± S.D.  
Increase in  
weight (mg) 
AM ± S.D.  
Percent increase  
in weight* 
AM ± S.D.  
1 
2 
3 
4 
5 
6 
7 
 
0 
5 
10 
15 
20 
25 
30 
 
18.597 ± 0.243 
28.148 ± 3.757 
35.623 ± 2.240 
44.948 ± 2.755 
51.622 ± 2.325 
60.962 ± 2.404 
62.034 ± 3.112 
 
0.000 
9.551 ± 1.613 
17.026 ± 2.191 
26.343 ± 2.605 
33.025 ± 2.370 
42.365 ± 2.306 
43.437 ± 3.262 
 
0.000 
51.357 ± 15.403 
91.552 ± 9.608 
141.857 ± 9.894 
177.582 ± 11.747 
227.805  ± 9.076 
233.569  ± 17.673 
 
 * Each reading was an average of three determinations  
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Table 13:Swelling studies of repaglinide patch F3  - Change in weight  
Sl. 
no.  
Time 
(min) 
Weight of  
patch (mg) 
AM ± S.D.  
Increase in  
weight (mg) 
AM ± S.D.  
Percent increase  
in weight* 
AM ± S.D.  
1 
2 
3 
4 
5 
6 
7 
 
0 
5 
10 
15 
20 
25 
30 
 
17.771 ± 0.797 
22.505 ± 2.685 
30.845 ± 1.733 
39.543 ± 3.504 
45.198 ± 4.402 
58.207 ± 3.263 
69.474 ± 2.979 
 
0.000 
4.734 ± 2.317 
13.074 ± 1.601 
21.772 ± 3.053 
27.427 ± 4.156 
40.436± 2.748 
51.703 ± 2.506 
 
0.000 
26.630 ± 12.295 
73.567 ± 11.246 
122.518 ± 15.048 
154.338 ± 23.294 
227.533 ± 13.295 
290.945 ± 13.882 
 
   * Each reading was an average of three determinations.  
 
Table 14:  Swelling studies of repaglinide patch F 4  - Change in weight  
Sl. 
no.  
Time 
(min) 
Weight of  
patch (mg) 
AM ± S.D.  
Increase in  
weight (mg) 
AM ± S.D.  
Percent increase  
in weight* 
AM ± S.D.  
1 
2 
3 
4 
5 
6 
7 
 
0 
5 
10 
15 
20 
25 
30 
 
22.813 ± 0.359 
49.214 ± 0.509 
64.570 ± 1.534 
86.870 ± 1.850 
99.026 ± 1.904 
110.227 ± 1.192 
128.673 ± 2.385 
 
0.000 
26.401 ± 0.444 
41.757 ± 1.955 
64.057 ± 1.447 
76.213 ± 1.503 
87.414 ± 1.050 
105.86 ± 1.979 
 
0.000 
115.728 ± 4.136 
183.040 ± 5.955 
280.791 ± 4.220 
334.077 ± 4.469 
383.176  ± 9.435 
464.336 ± 5.425 
 
   * Each reading was an average of three determinations.  
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Table 15: Swelling studies of Repaglinide patch F5  -  Change in weight  
Sl. 
no.  
Time 
(min) 
Weight of  
patch (mg) 
AM ± S.D.  
Increase in  
weight (mg) 
AM ± S.D.  
Percent increase  
in weight* 
AM ± S.D.  
1 
2 
3 
4 
5 
6 
7 
 
0 
5 
10 
15 
20 
25 
30 
 
21.926 ± 0.426 
45.238 ± 1.424 
60.567 ± 2.127 
74.282 ± 2.457 
88.614 ± 0.747 
110.160 ± 1.062 
130.241 ± 1.337 
 
0.000 
23.312 ± 1.848 
38.641 ± 2.550 
52.356 ± 2.853 
66.688 ± 0.445 
88.234 ± 0.776 
108.31 ±1.456 
 
0.000 
106.321 ± 10.555 
176.233 ± 14.635 
238.785 ± 16.451 
304.150 ± 4.202 
402.417 ± 4.636 
493.992 ± 10.509 
 
       * Each reading was an average of three determinations.  
 
 
Figure 18:Swelling studies of repaglinide patches - Change in weight 
in phosphate buffer,  pH 7.4.  
 
 The data for the increase in area due to swelling are given in 
Tables 11 to 15, respectively for patches F 1  to F5 .   The data are shown 
Time(minutes) 
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in Figure 18. Swelling was more pronounced in patches F 5  and F4  
which contain more of HPMC, which is hydrop hilic polymer.   Patches 
F1  and F2  showed lesser increase in area due to swelling. This must be 
due to the presence of higher concentrations of Ethyl cellulose.  The 
order of patches for their increase in area due to swelling is F 1< F3< 
F2< F4< F5 .   This was in agreement with the increase in weight due to 
swelling.  
Table 16: Swelling studies of repaglinide patch F 1  - Changes in area  
Sl. 
no.  
Time 
(min) 
Area of patch 
cm2  
AM ± S.D.  
Increase in  
area, cm2  
AM ± S.D.  
Percent increase  
in area* 
AM ± S.D.  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
 
1 
1.0231 ± 0.015 
1.0435 ± 0.034 
1.0501 ± 0.015 
1.0679 ± 0.031 
1.0717 ± 0.016 
1.0871 ± 0.027 
1.0923 ± 0.066 
1.1111 ± 0.089 
1.1210 ± 0.093 
1.1321 ± 0.061 
1.1428 ± 0.054 
1.1550 ± 0.018 
 
0 
0.0231 ± 0.015 
0.0435 ± 0.034 
0.0501 ± 0.015 
0.0679 ± 0.031 
0.0717 ± 0.016 
0.0871 ± 0.027 
0.0923 ± 0.066 
0.1111 ± 0.089 
0.1210 ± 0.093 
0.1321 ± 0.061 
0.1428 ± 0.054 
0.1550 ± 0.018 
 
0 
2.3100 ± 1.472 
4.3533 ± 3.438 
5.0100 ± 1.524 
6.7900 ± 3.066 
7.1733 ± 1.582 
8.7167 ± 2.680 
9.2367 ± 6.640 
11.1167 ± 8.905 
12.1033 ± 9.276 
13.2167 ± 6.130 
14.2800 ± 5.387 
15.5033 ± 1.830 
 
* Each reading was an average of three determinations.  
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Table 17:  Swelling studies of repaglinide patch F2-Changes in area  
Sl.  
no.  
Time 
(min) 
Area of patch 
cm2  
AM ± S.D.  
Increase in  
area, cm2  
AM ± S.D.  
Percent 
increase 
in area* 
AM ± S.D.  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
 
1 
1.0207 ± 0.026 
1.0596 ± 0.047 
1.0801 ± 0.015 
1.1067 ± 0.015 
1.1236 ± 0.016 
1.1384 ± 0.016 
1.1464 ± 0.043 
1.1558 ± 0.050 
1.1613 ± 0.045 
1.1705 ± 0.051 
1.1854 ± 0.062 
1.1915 ± 0.078 
 
0 
0.0207 ± 0.026 
0.0596 ± 0.047 
0.0801 ± 0.015 
0.1067 ± 0.015 
0.1236 ± 0.016 
0.1384 ± 0.016 
0.1464 ± 0.043 
0.1558 ± 0.050 
0.1613 ± 0.045 
0.1705 ± 0.051 
0.1854 ± 0.062 
0.1915 ± 0.078 
 
0 
2.0700 ± 2.565 
5.9600 ± 4.704 
8.0100 ± 1.524 
10.6700 ± 1.542 
12.3600 ± 1.559 
13.8400 ± 1.593 
14.6400 ± 1.350 
15.5800 ± 2.006 
16.1300 ± 1.464 
17.0500 ± 1.115 
18.5400 ± 1.237 
19.1500 ± 2.753 
 
* Each reading was an average of three determinations.  
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Table 18: Swelling studies of Repaglinide patch F3  -  Changes in area  
Sl. 
no.  
Time 
(min) 
Area of patch 
cm2  
AM ± S.D.  
Increase in 
area, cm2  
AM ± S.D.  
Percent 
increase 
in area* 
AM ± S.D.  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
 
1 
1.0336 ± 0.015 
1.0852 ± 0.030 
1.1379 ± 0.031 
1.2103 ± 0.047 
1.2563 ± 0.016 
1.2830 ± 0.017 
1.3112 ± 0.034 
1.3547 ± 0.007 
1.3844 ± 0.010 
1.4300 ± 0.017 
1.4601 ± 0.017 
1.4710 ± 0.035 
 
0 
0.0336 ± 0.015 
0.0852 ± 0.030 
0.1379 ± 0.031 
0.2103 ± 0.047 
0.2563 ± 0.016 
0.2830 ± 0.017 
0.3112 ± 0.034 
0.3547 ± 0.007 
0.3844 ± 0.010 
0.4300 ± 0.017 
0.4601 ± 0.017 
0.4710 ± 0.035 
 
0 
3.3600 ± 1.472 
8.5200 ± 2.996 
13.7900 ± 3.066 
21.0367 ± 4.734 
25.6367 ± 1.617 
28.3067 ± 1.651 
31.1233 ± 3.354 
35.4700 ± 0.710 
38.4467 ± 0.993 
43.0033 ± 1.726 
46.0167 ± 1.738 
47.1067 ± 3.539 
 
* Each reading was an average of three determinations.  
 
 
 
 
 
68 
Table 19: Swelling studies of repaglinide patch F4  - Changes in area  
Sl. 
no.  
Time 
(min) 
Area of patch 
cm2  
AM ± S.D.  
Increase in  
area, cm2  
AM ± S.D.  
Percent 
increase 
in area* 
AM ± S.D.  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
 
1 
1.0336 ± 0.015 
1.0592 ± 0.015 
1.1115 ± 0.040 
1.1379 ± 0.031 
1.1756 ± 0.018 
1.1856 ± 0.018 
1.2103 ± 0.047 
1.2693 ± 0.043 
1.3065 ± 0.043 
1.3847 ± 0.043 
1.4929 ± 0.058 
1.6223 ± 0.077 
 
0 
0.0336 ± 0.015 
0.0592 ± 0.015 
0.1115 ± 0.040 
0.1379 ± 0.031 
0.1756 ± 0.018 
0.1856 ± 0.018 
0.2103 ± 0.047 
0.2693 ± 0.043 
0.3065 ± 0.043 
0.3847 ± 0.043 
0.4929 ± 0.058 
0.6223 ± 0.077 
 
0 
3.3600 ± 1.472 
5.9200 ± 1.490 
11.1500 ± 1.036 
13.7900 ± 2.066 
17.5600 ± 1.758 
18.5600 ± 1.758 
21.0267 ± 1.734 
26.9367 ± 2.311 
30.6500 ± 1.268 
38.4667 ± 2.320 
49.2900 ± 1.750 
62.2300 ± 1.658 
 
* Each reading was an average of three determinations.  
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Table 20: Swelling studies of repagl inide patch F5  -Changes in area  
Sl. 
no.  
Time 
(min) 
Area of patch 
cm2  
AM ± S.D.  
Increase in  
area, cm2  
AM ± S.D.  
Percent 
increase 
in area* 
AM ± S.D.  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
 
1 
1.0421 ± 0.015 
1.1113 ± 0.015 
1.1726 ± 0.017 
1.2476 ± 0.017 
1.2851 ± 0.015 
1.3419 ± 0.034 
1.3752 ± 0.046 
1.4003 ± 0.017 
1.4600 ± 0.017 
1.5901 ± 0.017 
1.6707 ± 0.031 
1.7811 ± 0.018 
 
0 
0.0421 ± 0.015 
0.1113 ± 0.015 
0.1726 ± 0.017 
0.2476 ± 0.017 
0.2851 ± 0.015 
0.3419 ± 0.034 
0.3752 ± 0.046 
0.4003 ± 0.017 
0.4600 ± 0.017 
0.5901 ± 0.017 
0.6707 ± 0.031 
0.7811 ± 0.018 
 
0 
4.2100 ± 1.472 
11.1300 ± 1.524 
17.2567 ± 1.738 
24.7600 ± 1.732 
28.5133 ± 1.518 
34.1867 ± 3.354 
37.5167 ± 4.641 
40.0267 ± 1.703 
46.0033 ± 1.726 
59.0167 ± 1.738 
67.0700 ± 3.065 
78.1133 ± 1.778 
 
     * Each reading was an average of three determinations.  
70 
 
Figure 19 :Swelling studies of repaglinide patches - Change in area in 
phosphate     buffer, pH 7.4.  
Tensile Strength of Films  
 Tensile strength was determined using Hounse Field universal  
testing machine for drug-loaded fi lms. The results (average of 3 
determinations) are given in the Table 26 and the graph is represented 
in the Figure 22.The order of tensile strength of the fi lms is F1  
<F2<F3<F4<F5 .   The tensile strengths of drug loaded films were higher 
than dummy films.  This is justified because dissolved repaglinide 
strengthened the bonding of polymer chains.  With increase in HPMC 
proportion the tensile strength of f ilms was increased.  It  reflects that  
the soluble polymer develops cross linking better than insoluble 
polymer.  This is in agreement with the viscosity determinations.  More 
the solubility of the polymer higher will be the tensile strength.  
 
 
Time (mins) 
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Table 21: Data of tensile strength of F 1  to F5  formulation  
S.D. = Standard deviation, n  = 3  
S.No. Film 
Tensile strength 
(Kg + S.D.) 
Extension in 
length(mm) 
1 F1  
Blank 0.5262 + 0.0431 2.04±0.03 
Drug 0.6632 + 0.0342 12.71±0.04 
2 F2  
Blank 0.597 + 0.0128 5.46±0.02 
Drug 0.717 + 0.0170 7.14±0.03 
3 F3  
Blank 1.233 + 0.265 2.10±0.04 
Drug 1.473 + 0.220 7.66±0.02 
4 F4  
Blank 1.416 +0.306 11.25±0.03 
Drug 1.749 +0.216 15.79±0.02 
5 F5  
Blank 1.660 + 0.265 1.61±0.02 
Drug 1.956 +0.147 2.10±0.03 
 
 
Figure 20:  Tensile strength of films determined using Hounse Field 
universal testing machine  for the blank and drug loaded films.  
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Folding Endurance  
The recorded folding endurance of the films was > 300 times.  It  
means all  formulations had good film properties.  
Water Vapour Transmission Rate (WVTR)  
The water vapour transmission rates of different formulations 
were evaluated and the results are shown in Table 22.  
Repaglinide patches containing HPMC alone showed higher 
WVTR as compared to the formulations containing Ethyl c ellulose.  
This may be due to the HPMC, which is more hydrophilic in nature 
than Ethyl cellulose, which is less permeable to water vapour. 
Formulation F5  showed highest WVTR where as F 1  showed lowest 
WVTR. 
Table 22:Water vapour transmission rate of F 1  to F5  formulations  
Sl.  
No. 
Formulation 
Code 
Water vapour transmission 
rate (WVTR) 
Mean ± S.D.*x 10 -3  
1 F1  0.142 ± 0.065 
2 F2  0.151 ± 0.039 
3 F3  0.207 ± 0.029 
4 F4  0.312 ± 0.018 
5 F5  0.378 ± 0.021 
 
        *Standard deviation, n  = 3 
Drug Content Uniformity  
Drug content of the film was carried out to ascertain that the 
drug is uniformly distributed into the formulation. The film of size 2   
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2 cm2  was cut and placed in a volumetric flask. Ten ml of methanol was 
added and the contents were stirred in a shake r bath for 24 h to 
dissolve the film.  Subsequent dilutions were made with phosphate 
buffer (pH 7.4).  The absorbance of the solution was measured against 
the corresponding blank solution at 237 nm using UV -VIS 
spectrophotometer. The results obtained are rep resented in the           
Table 23.  
From the results obtained (i .e., lowest S.D. values), it  was clear 
that there was proper distribution of repaglinide in the film 
formulations. Hence it was concluded that drug was uniformly 
distributed in all the formulations.  
Table 23:Drug content of F1  to F5  formulations  
Sl.    
No. 
Formulation 
code 
Drug content (mg)  
Trial 
1 
Trial 
2 
Trial 
3 
Mean   S.D.* 
1 F1  1.267 1.372 1.305 1.294   0.0531 
2 F2  1.201 1.147 1.399 1.279   0.0807 
3 F3  1.223 1.298 1.333 1.290   0.081 
4 F4  1.278 1.302 1.291 1.310   0.0451 
5 F5  1.334 1.258 1.226 1.391   0.0887 
             *Standard deviation, n  = 3 
Dose calculation  
 The total dose of repaglinide for one daily sustained release 
formulation was calculated by following equation usin g the available 
pharmacokinetic data  
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DT= D IR  (1+0.693* t /  t1 /2) 
DT = Total  dose of drug  
D IR  = Dose of immediate release part  
t  = Time during which (S R) is desired (24 hours)  
t1 /2= Half life of drug (3hours)  
 
        F * total dose                0.7*16 
Cs s=  =   = 0.0094 
               Clp  *  ј                          394 * 3 
 
             Cs s  * Vd               0.0094 * 2 * 60  
DIR=  =   = 1.16 mg  
  F                        0.7  
C s s  = Steady state concentration of drug in plasma  
Clp  = Plasma clearance of drug  
 Ј = Frequency of dosing  
Vd = Volume of dug distribution  
F = Fraction of drug absorbed  
       (Clp ,  j ,  Vd and F are obtained from literature)  
Thus DT= 1.61(1+ 0.693 * 24/3)  
         DT= 10.54 is equivalent to = 10 mg  
 According to the theoretical release pattern, once daily 
repaglinide sustained release formulation should release 1.61 mg in one 
hour, 0.365mg every hour and 100% in 24 hours.  
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Table 24: Dissolution profile of repaglinide according to theoretical 
calculation is as follows  
Sampling time(h)  %Drug release 
0 0 
1 16.10 
2 19.75 
4 27.70 
6 34.35 
8 41.65 
12 56.25 
16 70.85 
20 85.45 
24 100.0 
 
 
Figure 21 Dissolution profile of Repaglinide according to theoretical 
calculation 
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In Vitro Release Studies  
In vitro release studies of repaglinide fi lms were carried out in 
phosphate buffer (pH 7.4).  The release data of repaglinide are given in 
Tables25to 29, respectively for patches F 1  to F5  repaglinide.  
Table25: In vitro  release of repaglinide from film F1  in phosphate 
buffer (pH 7.4) 
 
Time 
(hours) 
Cumulative * 
drug released 
(mg) AM ± S.D 
% Drug 
released 
% Drug 
remain 
unreleased 
log% drug 
remain       
unreleased 
0 
1 
2 
4 
6 
8 
12 
16 
20 
24 
0 
  0.7550 + 0.077 
  0.9001 +0.081 
1.0811 +0.052 
1.1028 +0.030 
1.3280 + 0.042 
1.0166 + 0.070 
1.0042 + 0.040 
1.0094  + 0.048 
1.0036 + 0.110 
0 
7.55 
16.551 
27.362 
38.390 
42.476 
48.049 
55.495 
62.832 
69.684 
100 
97.617 
83.449 
72.638 
61.610 
57.524 
51.051 
44.505 
37.168 
30.316 
2 
1.9895 
1.9214 
1.8611 
1.7895 
1.7598 
1.7080 
1.6484 
1.5701 
1.4816 
 
* Each reading is an average of three determinations.  
   Initial  drug concentration = 0.7550mg 
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Figure 22: In vitro  release of repaglinide from film F 1  in phosphate 
buffer (pH 7.4)  
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Table 26: In vitro release of Repaglinide from film F2  in phosphate 
buffer (pH 7.4) 
Time 
(min) 
Cumulative *  
Drug released 
(mg) AM ± 
S.D. 
% Drug 
Released 
% Drug 
remain 
unreleased 
Log % drug 
remain 
unreleased 
0 
1 
2 
4 
6 
8 
12 
16 
20 
24 
0 
0.2435 + 0.030 
0.5014 + 0.113 
0.7353 + 0.071 
1.0325 + 0.069 
1.1792 + 0.083 
1.3115 +0.039 
1.3629 + 0.041 
1.4020 + 0.060 
1.4992 + 0.070 
0 
2.435 
5.014 
7.353 
18.325 
24.948 
51.947 
60.550 
71.107 
78.005 
100 
45.6453 
43.9241 
39.8635 
35.9565 
33.0514 
28.0521 
25.4498 
22.8920 
17.9947 
2 
1.6593 
1.6427 
1.6005 
1.5557 
1.5191 
1.4479 
1.4056 
1.3596 
1.2551 
  *Each reading was an average of three determinations  
    Initial drug concentration = 0.2435 mg.  
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Figure 25:In vitro  release of repaglinide from film F 2  in phosphate 
buffer (pH 7.4)  
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Table 27:In vitro  release of repaglinide from film F 3  in phosphate  
buffer (pH 7.4)  
 
Time 
(hour
s) 
Cumulative * 
drug released 
(mg) AM ± S.D.  
% Drug 
released 
% Drug 
remain 
unreleased 
log% drug 
remain       
unreleased 
0 
1 
2 
4 
6 
8 
12 
16 
20 
24 
 
0 
1.6014 + 0.021 
0.3657+ 0.017 
0.6921 + 0.021 
0.7137 + 0.017 
0.7443 + 0.082 
0.7906 + 0.035 
1.4261 + 0.026 
1.4672 + 0.035 
1.3224 + 0.025 
 
0 
16.014 
20.564 
28.715 
34.361 
42.024 
56.544 
70.318 
85.244 
98.249 
 
100 
83.986 
78.436 
71.285 
65.639 
57.976 
43.456 
29.682 
14.756 
1.751 
 
2 
1.9242 
1.8975 
1.8529 
1.8171 
1.7632 
1.6377 
1.4724 
1.1689 
0.2432 
 
*Each reading was an average of three determinations  
  Initial drug concentration= 1.6014 mg.  
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Figure 24:In vitro  release of repaglinide from film F 3  in phosphate 
buffer (pH 7.4)  
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Table 28: In vitro  release of repaglinide from fi lm F 4  in phosphate 
buffer (pH 7.4)  
Time 
(hours) 
Cumulative * 
drug released 
(mg) AM ± S.D 
% Drug 
released 
% Drug 
remain 
unreleased 
log% drug 
remain       
unreleased 
0 
1 
2 
4 
6 
8 
12 
16 
20 
 
 
0 
0.7550 + 0.077 
1.2001 +0.081 
1.3811 +0.052 
1.5028 +0.030 
1.6280 + 0.042 
1.7166 + 0.070 
1.8542 + 0.040 
1.9294  + 0.048 
 
0 
7.550 
12.870 
24.087 
45.251 
64.476 
77.049 
89.495 
99.000 
 
100 
92.450 
87.130 
75.913 
54.785 
35.524 
22.951 
10.505 
1.000 
 
2 
1.9659 
1.9401 
1.8803 
1.7386 
1.5504 
1.3608 
1.0213 
0 
 
  *Each reading was an average of three  determinations  
    Initial drug concentration = 0.7550mg  
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Figure 27:In vitro  release of repaglinide from film F 4  in phosphate 
buffer (pH 7.4)  
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Table 29:In vitro  release of repaglinide from film F 5  in phosphate 
buffer (pH 7.4)  
Time 
(hours) 
Cumulative 
drug* released 
(mg) 
AM ± S.D.  
% Drug 
released 
% Drug 
remain 
unreleased 
log% drug 
remain       
unreleased 
0 
1 
2 
4 
6 
8 
 
0.000 +0.000 
1.8209 + 0.381 
2.5849 + 0.417 
2.9029 + 0.063 
3.1911 + 0.042 
3.2573 + 0.042 
 
0 
35.0982 
48.2311 
75.1650 
89.5429 
100 
 
100 
64.9017 
51.7689 
24.8349 
10.4571 
0 
 
2.000 
1.8122 
1.7140 
1.3950 
1.0194 
0 
 
*Each reading was an average of three determinations  
   Initial  drug concentration = 1.8209 mg.  
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Figure 28:In vitro  release of repaglinide from film F 5  in phosphate 
buffer (pH 7.4)  
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The in vitro  release data for repaglinide from films are compiled in 
Table 30.  
Table 30:Compilation of in vitro  release of repaglinide at 24 h  
Sl. No.  Film code % Drug released 
1 F1  69.68 
2 F2  78.00 
3 
4 
5 
F3  
F4  
F5  
98.24 
99.00* 
100** 
           *20 h and ** 8 h  
 
 A perusal to Figures 22 to 26, and Table 26 and 25 indicated that  
the release of Repaglinide was faster in films containing more 
concentration of HPMC.  
Drug permeation profiles from formulations F 1  to F5  are shown 
in Figure 30.  Perusal to Figure 26 indicates that 100 % of drug was 
released within 8 h from F 5  and followed zero-order kinetics.  This 
means the film has to be applied several times a day to maintain 
therapeutic levels constant.  The faster drug rele ase rate is due to the 
use of hydrophilic polymer (HPMC) alone.  To get sustained release,  
copolymer that  decreases the drug release rate is  needed to be added.  
Therefore, rate-controlling membranes of Ethyl cellulose were cast  
with the aim to achieve controlled release of repaglinide from drug 
reservoirs of HPMC.   
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Perusal to Figure 23 indicates that, the cumulative amount of 
drug released after 24 h from F 2  was found to be 78.00 % when 
compared to F1  the drug release from F 2  was increased from 20% .  
This effect was because of the copolymer, HPMC, which acted as the 
rate-controlling polymer.  However, the target is to get drug release up 
to 24 h.   Hence there is a need to delay the drug release further.   
The sustained drug release could be achieved by in creasing the 
copolymer concentration in the formulation by maintaining the total  
polymer concentration same i.e., 400 mg.  In the formulations F 2  to F5 ,  
HPMC was increased in order.  From Figure 24, it  was found that only 
98.249% of repaglinide was released from F3  at the end of 24 h.  
In the formulations F4  and F5 ,  an attempt was made by adding 
more concentration of HPMC to get the required release rate.  In the 
formulation F4  and F5  the drug release was found to faster because of 
further increase in concentration of HPMC which is highly hydrophobic 
in nature.  
In the formulation F3 ,  both HPMC and Ethyl cellulose was 
equally added.  The drug release from this fi lm was found to be 
98.02%.  When compared to F 1  and F2 ,  20% drug release was improved.  
Hence, the use of HPMC was a successful attempt.   But the thirst for 
improving the formulation continued to develop further.  
All the formulations (F1  to F5) released drug in a biphasic 
pattern,  i .e.  a faster release that occurred for first  hour, after which the 
release rate slowed down. This result  can be explained from the 
theoretical point of view. Ethyl cellulose being an inert  polymer,  
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solvent penetration into the film was rate–limiting factor for the 
release of the active principle. At the beginning of the pro cess, the 
active substance at and near the surface of the film dissolves quickly.  
When the dissolution process advances,  there is a greater resistance to 
the penetration of the solvent in the inside of the matrix film, due to 
the non-hydrophilici ty of the polymer and the decreasing length of the 
solvent front. The drug, easily accessible by water immediately 
dissolves and diffuses from the interface between the film surface and 
surrounding media after which diffusion process slows down. The 
formulations can be arranged in order of release rate as:  F 1  < F2  < F3  < 
F4  < F5 .  
 
Figure 27:In vitro release of Repaglinide from films F 1  to F5 .  
Kinetics of  drug release (Zero and First Order) 
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Zero order release  
 
Figure 28:In vitro release of Repaglinide from film F 1  in phosphate 
buffer (pH 7.4).  
First order release  
 
 
Figure 29:In vitro release of Repaglinide  from film F1  in phosphate 
buffer (pH 7.4).  
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Zero order release  
 
Figure 30:In vitro release of Repaglinide from film F2  in phosphate 
buffer (pH 7.4).  
 
First order release 
 
Figure 31:In vitro release of Repaglinide from film F2  in phosphate 
buffer (pH 7.4).  
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Zero order release  
 
Figure 32:In vitro release of Repaglinide from film F 3  in phosphate 
buffer (pH 7.4).  
 
First order release  
 
Figure 33:In vitro release of Repaglinide from film F 3  in phosphate 
buffer (pH 7.4).  
 
92 
Zero order release  
 
Figure 34:In vitro release of Repaglinide from film F 4  in phosphate 
buffer (pH 7.4).  
 
First order release  
 
Figure 35:In vitro release of Repaglinide from film F 4  in phosphate 
buffer (pH 7.4).  
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Zero order release  
 
Figure 36:In vitro release of Repaglinide from film F 5  in phosphate 
buffer (pH 7.4).  
First order release  
 
Figure 37:In vitro release of Repaglinide from film F 5  in phosphate 
buffer (pH 7.4).  
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The release data of  repaglinide are processed into graphs (Figures 30 to 
39) to understand the linear relationship, i .e. ,  kinetic principles. The 
data were processed for regression analysis using MS -Excel statistical  
functions. The parameters and equations are given in the T able 31. 
Table 31: Comparison of orders of in vitro release Repaglinide from 
films F1  to F5  
Film code 
In vitro  release in phosphate buffer pH 6.8  
regression equations 
Zero order First order 
F1  
y = -0.021x + 1.745 
R² = 0.771 
Log y = -2.741x + 89.08 
R² = 0.89 
F2  
y =-0.021x + 1.745 
R² = 0.771 
Log y = -1.972x + 57.62 
R² = 0.508 
F3  
y = -0.057x + 2.109 
R² = 0.817 
Log y = -3.748x + 89.56 
R² = 0.983 
F4  
y = -0.087x + 0.166 
R² = 0.892 
Log y = -5.191x + 93.16 
R² = 0.945 
F5  
y = -0.228x + 2.123 
R² = 0.919 
Log y = -11.60x + 82.61 
R² = 0.909 
 
A perusal to the Table 31 indicated that the regression values of 
film F1  and F2  are higher with zero order and therefore the release 
kinetics followed zero order from these two films and films F 3  to F5  are 
higher with first order and therefore the release kinetics followed first 
order from these films.  
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Release Mechanisms 
To study the release mechanisms of repaglinide the data of in  
vitro drug release was verified using Higuchi ’s model, Korsmeyer-
Peppas model, and Hixon-Crowell  cube root law models.  
 
Figure 38:In vitro  release profile Repaglinide from of F-3 fitted in 
Higuchi’s Plot  
 In order to explore more precise mechanism of release of 
repaglinide from in house developed matrix tablets, the dissolution 
data was also fit ted to the well-known exponential  equation 
(Korsmeyer equation) as shown in the Figure 40, which is often used to 
describe the drug release behaviour from polymeric systems.  
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Figure 39: In vitro  release profile of Repaglinide from F-3 fit ted in 
Korsmeyer’s Plot.  
 
Table32: Fitting of the Hixon-Crowell  cube root law for in vitro 
release of Repaglinide from F-3 
Time in hours  M0 1 /3  –M1 /3  
0 0.000 
1 0.170 
2 0.249 
4 0.343 
8 0.468 
12 0.597 
16 0.846 
20 1.019 
24 1.300 
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Figure 40: Fitting of the Hixon-Crowell cube root law for in vitro 
release of  Repaglinide from F-3
 
 
Table 33: Regression equations of in vitro release of repaglinide from 
the film F-3 
Formulation 
In vitro  release of repaglinide from the formulation of F -
3 
Hixon-Crowel 
model  
Higuchi’s model  
Korsmeyer 
Peppas model  
F3
 
y = 0.048x + 0.09  
 
R² = 0.982 
y = 18.84x + 
0.575 
R² = 0.994 
y = 0.446x + 
1.341 
R² = 0.993 
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Application of Hixon–Crowell  cube root law, the equation (M 0 1 /3  
–  M1 /3) = kt ,  provides information about the release mechanism, na mely 
dissolution rate limited. Application of Higuchi ’s equation (M = K t1 /2) 
provides information about the release mechanism, namely diffusion 
rate limited. Korsmeyer -Peppas model indicates that release mechanism 
is not well known or more than one type o f release phenomena could be 
involved. The  'n '  value could be used to characterize different release 
mechanisms as:  
 
Table 34: Slope of Korsmeyer-Peppas equation and proposed release 
mechanisms 
Slope ( n  )  Mechanism 
<0.5 Fickian diffusion (Higuchi 
Matrix)  
0.5 <n< 1 Non-Fickian diffusion  
1 Case II transport   
  
The data of average values were processed as per Hixon -Crowell  
cube root law and are given in the Tables 32 and the Figure 40. The 
data of average values were processed as per Higuchi ’s equation and 
are represented in the Figure 38. The data of average values were 
processed as per Korsmeyer -Peppas model and are represented in the 
Figure 39. The linearity of data for all  the models was identified from 
the Figures. The equations were generated thro ugh statistical  
procedures and reported in the Table 33.  
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Perusal to the Figure 40 indicates that R2  values are higher for 
the Higuchi’s model compared to Hixon –  Crowell for the F-3. Hence 
repaglinide release from the tablets of F -3 followed diffusion ra te 
controlled mechanism.  
According to Korsmeyer-Peppas model,  a value of slope < 0.5 
indicates the Fickian diffusion (Higuchi Matrix) and hence release 
mechanism from F-3 follows Fickian diffusion (Higuchi Matrix).  
Stability Studies  
 Optimized medicated patches were subjected to short term 
stability testing. Films were placed in a glass beaker l ined with 
aluminum foil and kept in a humidity chamber maintained at 40 + 2 oC 
and 75 + 5% RH for 1 month as per ICH guidelines. Changes in the 
appearance and drug content of the stored films were investigated after 
storage. The data presented were the mean of three determinations. 
Percentage drug present in the films was determined 
spectrophotometrically and reported in the Table 35 and represented in 
the Figure 43.  Percentage decrease in drug content in all the films was 
also calculated and reported in the Table 35  and represented in the 
Figure 41. Perusal to Tables 35, the Figures 41 indicated that the drug 
loss is less though the films were stored for one month.  
The films were also observed for the ir appearance and texture. 
These properties did not change in all the films during the period of 
study.   
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Table 35: Percentage drug present in repaglinide film F -3 
Time (hours)  Zero day After 30 days  
0 0.0 0.0 
1 16.01 14.86 
2 20.56 19.72 
4 28.71 29.02 
6 34.39 33.12 
8 42.02 41.59 
12 56.54 55.32 
16 70.32 70.46 
20 85.24 84.67 
24 98.24 96.48 
 
 
 
Figure 41:  Percentage drug present in repaglinide films F -3 during one 
month storage.  
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 The percent drug of repaglinide from init ial concentration 100% 
was found to be decreased by 3.52% 
From the results obtained and the discussion generated from 
them, encouraged conclusions were drawn and presented in the next 
chapter “conclusion” .  
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SUMMARY 
Introduction 
 Transdermal drug delivery systems (TDDS) are adhesive drug 
containing devices of defined surface area that delivers predetermined 
amount of drug to the intact skin at  a pre  programmed rate. The 
transdermal delivery has gained importance in recent years. T he 
transdermal drug delivery system has potential advantages of avoiding 
hepatic first  pass metabolism, maintaining constant blood levels for 
longer period of time resulting in a reduction of dosing frequency,  
improved bioavailability,  decreased gastrointe stinal irritation that 
occur due to local contact with gastric mucosa, and improved patient 
compliance.  Some of the anti diabetic drugs already have been 
formulated and evaluated as transdermal patches but most of them still  
been unexplored.  
Objectives  
In the present study transdermal films of the Repaglinide were 
prepared using polymers like HPMC K -100 and Eudragit RS100 alone 
and in different combinations.  These transdermal fi lms will  be 
characterized for their physicochemical properties including drug 
release.  
Review of Literature  
 The chapter ‘Literature Review’  contained the general concepts 
of transdermal drug delivery and its applications. Advantages and 
limitations of drug delivery through transdermal route were listed. 
Description of the physiology of skin for drug delivery was explained. 
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Factors affecting transdermal drug delivery system and possible routes 
for drug transport  across the skin layer were discussed. Basic 
components and modern approaches of transdermal drug delivery 
systems were described.  
Methodology 
At the outset, method for estimation of the drug was developed.  
Repaglinide showed maximum absorption at wavelength 237 nm in 
phosphate buffer pH 7.4 and 0.1 N HCl solutions. Standard calibration 
curve obeyed Beer ’s law at given concentration range of 1µ g/ml to 20 
µ g/ml which one subjected to regression analysis.  The value of 
regression coefficient was found to be 0.997, which showed linear 
relationship between concentration and absorbance. The FT -IR peak of 
repaglinide displayed some parent peaks at 400 to 4000 cm - 1nm. The 
physical mixture of drug with selected polymers gave peak which 
corresponded to the parent peaks of the pure drug which confirmed the 
compatibility between drug and selected polymers.   
The various formulations of films were developed for 
repaglinide, dose in given area of 15 cm 2  was 10 mg using various 
bioadhesive and film forming polymers like Ethyl cellulose and HPMC 
K-100 in single and, dibutyl  phthalate.  
Physicochemical parameters such as weight uniformity, thickness  
uniformity, swelling determinations, tensile strength determination, 
viscosity determination, and folding endurance studies were carried 
out. In order to know the pattern of release of Repaglinide from 
patches, in vitro release and skin permeation studies  were carried out 
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with dissolution apparatus  and diffusion cell using pH 7.4 phosphate 
buffers as receptor medium, Short -term stability studies were 
conducted.  
Results and Discussion 
The results and discussion obtained from different methods of 
this thesis were described under different tables and graphs. From the 
results of the drug content determination, it  was inferred that  there was 
proper distribution of drug in the films and the deviations were within 
the acceptable limits. Films exhibited higher tens ile strength as the 
concentration of HPMC was increased. The prepared film exhibited 
satisfactory physical characteristics such as weight uniformity,  
thickness uniformity, and folding endurance. Films containing HPMC 
alone showed higher WVTR as compared to  those containing Ethyl  
cellulose. This may be due to the HPMC which is more hydrophilic 
than, Ethyl cellulose, which is less permeable to water vapor. Release 
study of repaglinide films indicated that the drug release from the 
formulation F-3 showed satis factorial  result. Among all  the developed 
formations,  formulation containing HPMC K-100 and Ethyl cellulose,  
showed maximum rate of drug release of 98.2467 + 0.136 within 24 h. 
Hixon-Crowell cube root law was applied to test the release 
mechanism.  R2  values are higher for Higuchi ’s model compared to  
Hixon –  Crowell for the patchF3 .  Hence Repaglinide release from the 
patch F3  followed diffusion rate controlled mechanism. Repaglinide 
release from patches F4 ,  F5  followed dissolution rate controlled 
mechanism. The absorption kinetics was studied by regression analysis 
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(R2  =0.935).  The absorption of repaglinide followed first order.  
Stabili ty study of formulations showed no significant changes in the 
drug content as well as physical  characteristics of the patch es.   
Conclusion 
From the results obtained and discussion generated there from, 
encouraged conclusions were drawn and written in chapter.  On the 
basis of the in vitro characterization it was concluded that Repaglinide 
could be administered transdermally through matrix type TDDS 
developed in our laboratory. Transdermal patches consisting of the 
bioadhesive polymer HPMC K-100 and rate-controlling polymer of 
Ethyl cellulose demonstrated sustained and controlled release of the 
drug across during in vitro permeation studies. The drug remained 
intact and stable in the TDDS during storage, with no significant 
chemical interaction between the drug and the excipients. Further work 
is to establish the therapeutic utility of this system by 
pharmacokinetics and pharmacod ynamic studies on human beings.  
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CONCLUSION 
 
Repaglinide is one of the drugs, which is used for the 
management of type 2 diabetes. It  has only a short half -life of 1- 3 
hour and oral bioavailability is about45%. Therefore, the present 
investigation is concern with the development of the unidirectional 
transdermal films and to increase the bioavailabili ty of the drug and its 
half life.  
The following conclusions were drawn from results obtained;  
1)  A suitable method of analysis of repaglinide by UV Spect roscopy 
was developed. Repaglinide showed maximum absorption at 
wave length 237 nm in isotonic phosphate buffer (pH 7.4) and 
0.1 N HCl solutions. The value of regression coefficient of 
standard curve was found to be 0.995 which showed linear 
relationship between concentration and absorbance. 
Preformulation studies for drug-polymer compatibility by FTIR 
gave confirmation about their purity and showed no interaction 
between the drug and selected polymers.  
2)  Various formulations were developed by using release r ate 
controlling and bioadhesive polymers like Ethyl cellulose and 
HPMC K-100 in single and combinations by solvent casting 
methods with incorporation of dibutyl phthalate as plasticizer.  
3)  Developed transdermal films possessed the required 
physicochemical properties such as drug content uniformity,  
swelling index, folding endurance, weight uniformity, thickness 
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uniformity, tensile strength, and water vapour transmission rate 
(WVTR).  
4)  From the results of the drug content determination, it  was 
inferred that there was proper distribution of drug in the films 
and the deviations were within the acceptable limits.  
5)  Films exhibited higher tensile strength as the concentration of 
HPMC was increased.  
6)  Films containing HPMC alone showed higher WVTR as 
compared to those containing Ethyl cellulose.  
7)  Among all the developed formations,  formulation containing 
HPMC, Ethyl cellulose of equal amount F -3 showed maximum 
rate of drug release of 98.249 + 0.135 within 24 h.  
8)  Hixon-Crowell cube root law was applied to test the release 
mechanism. R2  values are higher for Higuchi ’s model compared 
to Hixon –  Crowell for the patches F3 .  Hence repaglinide release 
from the patch F3  followed diffusion rate controlled mechanism.  
9)  Stabili ty study of the formulations showed no significant 
changes in the drug content as well as physical characteristics of 
the film.  
FUTURE DIRECTION 
Long term stabil ity studies of the films.  
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